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Nothing in life is to be feared, 
it is only to be understood. 
 







Cancer is a multifactorial disease governed by oncogenes and tumor suppressors that not only 
impact on the behavior of the cancer cells but also influence many processes in the surrounding 
tumor microenvironment. The most studied tumor suppressor family is the p53 family, which 
consists of the transcription factors p53, p63 and p73. While p53 is the most frequently mutated 
gene in the cancer genome, for both p63 and p73, a shift in the balance between different 
isoforms has been discovered and this deregulation of protein levels has been linked to tumor 
progression and survival. P73 can be transcribed from two separate promoters resulting in a 
tumor suppressing, full-length isoform (TAp73), and a N-terminally truncated version 
(ΔNp73), which lacks the transactivation domain and thus possesses oncogenic properties. 
Furthermore, alternative splicing in the C-terminus results in a number of additional isoforms.  
P73 has been shown to be able to support and overtake many processes p53 is regulating. 
However, p73 isoforms have also been shown to have p53-independent functions. 
Understanding how different p53 family members regulate tumor development and 
progression is essential for identifying possible treatment strategies.  
In this thesis we identified several previously unknown roles for p73 isoforms in controlling 
the tumor microenvironment. Firstly, we discovered that loss of TAp73 results in a NF-κB-
dependent upregulation of pro-inflammatory factors in breast cancer. Furthermore, this led to 
a concurrent increase in tumor-promoting macrophage infiltration. Secondly, we identified a 
role for ΔNp73 in the regulation of activating NK cell ligand expression on cancer cells. 
However, we observed a concomitant upregulation of inhibitory NK cell ligands upon loss of 
ΔNp73, leaving NK cell-mediated killing of tumor cells unaffected. Thirdly, a correlation 
between high levels of ΔNp73 and HIF-1α protein was observed. We demonstrate that ΔNp73 
increases HIF-1α protein stability by interfering with the expression of genes of the ECV 
complex, normally involved in proteasomal degradation of HIF-1α. Finally, we further 
strengthen the involvement of ΔNp73 in the process of multidrug resistance. ΔNp73 was found 
to promote elevated expression of ABC transporters, ABCB1 and ABCB5, in breast cancer 
and melanoma, thereby supporting the efflux of drugs from the cancer cells and increasing their 
resistance to drug treatments.  
Taken together, these findings highlight the significant contributions of p73 isoforms on tumor 
progression and aid in unravelling the complex interactions of this network.   
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LIST OF ABBREVIATIONS 
  
ABC ATP-binding cassette 
ADCC Antibody-mediated cellular cytotoxicity 
Arg1 Arginase 1 
CAF Cancer associated fibroblast 
CBP CREB-binding protein 
CCL2 C-C motif chemokine ligand 2 
CCL5 Chemokine (C-C motif) ligand 5 
CCR2 C-C chemokine receptor type 2 
CSF-1 Colony stimulating factor 1 
CSF1R Colony stimulating factor 1 receptor 
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HER2 Human endothelial growth factor 
HIF-1α Hypoxia inducible factor 1 α 
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PDGFB Platelet-derived growth factor B 
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SIRPα Signal regulatory protein α 
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TAM Tumor associated macrophage 
TCGA The cancer genome atlas  
TGF-β Transforming growth factor β 
TLR Toll-like receptor 
TME Tumor microenvironment 
TNBC Triple negative breast cancer 
TNF-α Tumor necrosis factor α 
Treg Regulatory T cell 
ULBP UL binding protein 
VEGFA Vascular endothelial growth factor A 
VEGFC Vascular endothelial growth factor C 
VEGFR Vascular endothelial growth factor receptor 
VHL Von Hippel-Lindau protein 







According to the World Health Organization (WHO) cancer is the second leading cause of 
death worldwide with every sixed death caused by cancer 1. A tumor is defined as a mass of 
transformed cells proliferating at an abnormal rate, which can be benign or malignant. 
Malignant tumors are considered cancerous and can invade the surrounding tissues as well as 
spread to other organs resulting in metastasis.  
Multiple factors play a role in the development and progression of cancer. Ten hallmarks have 
been proposed to be essential for this process, including perpetual growth factor signaling, 
avoiding cell death through apoptosis, changes in cellular metabolism and the continuous 
accumulation of mutations through genetic instability (see Figure 1) 2.  
 
 
Figure 1. The hallmarks of cancer by Hanahan and Weinberg. 
 
Undeniably, one crucial factor tightly linked to cancer development and progression is the 
body’s own immune system 3. Other factors such as oxygen regulation and angiogenesis are 
also attributed a vast impact on cancer establishment 4. These fields of research together with 
multidrug resistance will be discussed throughout this thesis.  
Despite great achievements in the field of cancer research during recent years, numerous 
elements remain unknown and further detailed understanding is needed to reach a point where 
there can be effective treatment, or ultimately even a cure, for all people suffering from cancer. 
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1.1.1 Oncogenes and Tumor Suppressors 
Under normal circumstances, cell growth and division are tightly regulated processes where 
multiple checkpoints must be passed before progression to prevent replication of faulty DNA. 
Mutations in key regulator genes can lead to deviation in these processes and might result in 
unlimited and unregulated cell division, regardless of errors in DNA replication.  
 
Oncogenes 
Oncogenes were discovered by chance while studying RNA viruses. It was found that some 
viruses were able to transform normal cells to become cancerous. With time it was understood 
that these viruses carry genes that interfere with cellular processes and induce uncontrolled 
proliferation. These genes were called viral oncogenes. Back then, it was believed that all 
tumors derive from viral infections. However, later it was shown that homologues of most of 
these viral genes were present in the cellular genome and that viruses were not essential for 
tumor development 5. This meant that we carry multiple so-called proto-oncogenes in our 
genome, that can be converted into oncogenes and induce tumorigenesis. Often proto-
oncogenes belong to classes of genes that regulate cell growth and differentiation and their 
activation is strictly limited to specific events during cellular development. Proto-oncogenes 
can be growth factors (EGF, VEGF), growth factor receptors (EGFR, VEGFR), signal 
transducers (RAS, BRAF), protein kinases (SRC, ABL, AKT) and nuclear 
oncogenes/transcription factors (MYC, HIF) 6,7. Upon changes in genetic configuration (such 
as point mutations, amplifications or chromosomal rearrangements) these genes can become 
constantly activated and turn into oncogenes as which they promote uncontrolled growth 8. 
Oncogenes are therefore commonly referred to as the gas paddles of the cells.   
 
Tumor suppressors 
Conversely, tumor suppressors are usually called the brakes of the cells. Upon loss of their 
function cells gain the ability to overcome the strict regulation of cellular growth and division 
and gain the ability to replicate without hindrance. Tumor suppressors are genes that are often 
involved in processes such as DNA repair and cell cycle control. Unlike oncogenes, both alleles 
of the tumor suppressor gene must be altered to result in significant consequences for the cell. 
This phenomenon is referred to as Knudson’s two-hit hypothesis. Tumor suppressor genes can 
be dysfunctional due to deletion or inactivation, but also by epigenetic silencing or proteasomal 
degradation 9. However, there are exceptions to this rule. One example will be discussed later 
in the section P73. 
Undisputable, the most famous tumor suppressor up to date is p53, which will be discussed in 
more detail in the section ‘P73 – Part of the p53 family’ 10. Other major tumor suppressor genes 
are retinoblastoma (Rb), p16, PTEN, BRCA1/2, CDKN2A and VHL 7,11,12, which are involved 




1.1.2 Breast Cancer 
Breast cancer is the second most common cancer worldwide and the most common cancer in 
women (see Figure 2). Even though tremendous efforts have been made to fight this disease 
still in 2018 an estimate of 627,000 women died from breast cancer 13.   
 
  
Figure 2. Cancer incidences in females worldwide. 
 
Overall, even though a rise in incidence rates can be observed, breast cancer deaths have 
declined dramatically over the last three decades by up to 40 percent. This is mainly due to the 
implementation of screening programs that allow for detection of cancer at an earlier stage, but 
also due to advances in cancer therapies 14. Compared to other cancers, breast cancer now 
shows a rather good prognosis. In high-income countries the overall five-year survival rate for 
women diagnosed with breast cancer lies around 91 percent, while ten-year survival reaches 
84 percent 15. However, the statistics vary dramatically in low- and middle-income countries 
where breast cancer is often detected at a later stage. 
Anatomically, breast cancer can arise in the ducts (ductal carcinoma in situ (DCIS)) or in the 
lobes (lobular carcinoma in situ (LCIS)) of the breast tissue (see Figure 3). However, only 
DCIS has been found to progress to the stage of invasive breast cancer 16. 
First line of treatment for breast cancer consists of surgery, either mastectomy (complete 
removal of the breast) or breast-conserving surgery (removing only the tumor and surrounding 
tissue). Surgery is often accompanied by radiation, chemotherapy, hormonal or targeted 
therapy. Recently, for the first time an immunotherapeutic drug, namely a monoclonal antibody 
against the immune checkpoint protein PD-L1, in combination with chemotherapy has been 
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approved for triple negative breast cancer 17. Which treatment is selected depends on many 
factors, including the type, stage and spread of the breast cancer and the patient’s age. 
 
 
Figure 3. Anatomic location of breast cancer 
 
Subtypes of breast cancer 
Broadly, breast cancer can be classified into four molecular subtypes that differ greatly in 
prognosis and treatment options 18.  
 
Luminal A (HR+/HER2-) 
The majority of breast cancers, almost 75 percent, belong to the group of hormone receptor 
(HR) positive breast cancers. These cancers are defined by the expression of estrogen and/or 
progesterone receptors (ER/PR) on the cell surface 19. ER is a nuclear hormone receptor that 
functions as a transcription factor 20. PR is downstream of the ER signaling pathway, thus their 
expression usually correlates 21. Typically, the Luminal A subtype has a rather good prognosis 
due to a general good response to hormonal therapies. Patients with ER-positive cancers 
usually benefit from endocrine therapy which is targeting ER, such as Tamoxifen and 





Luminal B (HR+/HER2- or HR+/HER2+) 
Breast cancers of the Luminal B type are classified by the expression of HRs, however show 
lower levels than the Luminal A type. Additionally, some Luminal B tumors express the human 
epidermal growth factor 2 receptor (HER2). HER2 is a tyrosine kinase receptor located in the 
cell membrane, which is involved in cell proliferation and survival. In breast cancer, HER2 is 
often upregulated due to gene amplification or overexpression. Autophosphorylation of HER2 
heterodimers leads to the activation of signaling pathways important for cell proliferation and 
survival, including PI3K/AKT and RAS/RAF/MEK/ERK 24. Usually, the Luminal B subtype 
is also highly positive for Ki67 (>20%), a marker for rapid cell proliferation, which correlates 
with poor outcome 25. This leaves Luminal B cancers with a worse prognosis compared to the 
Luminal A subtype 26. 
HER2-enriched (HR-/HER2+) 
A small percentage of breast cancers show expression of HER2 without concomitant 
expression of HRs. Even though this group had the worst prognosis before, the current standard 
treatment are targeted therapies against HER2, which led to a drastic improvement of survival. 
So far, a few distinct options have been approved to target HER2: humanized monoclonal 
antibodies, such as trastuzumab; small molecular receptor tyrosine kinase inhibitors; and an 
antibody drug conjugate of trastuzumab 27-29. 
Triple negative breast cancer (HR-/HER2-) 
The final group is a heterogeneous group termed triple negative breast cancer (TNBC), which 
is defined by the absence of HR and HER2 expression and accounts for around 15-20% of all 
breast cancers 30. This group can be further divided into prognostically significant subtypes 
depending on their gene expression, including basal-like 1, basal-like 2 and 
immunomodulatory. Actually, 80% of TNBCs show mutations in p53 and p53 expression has 
been correlated with poor prognosis 31.TNBCs are considered to have the worst prognosis of 
all breast cancer subtypes, showing a five-year survival rate of around 77 percent. 
Unfortunately, so far, systemic treatment options are limited to different cytotoxic agents, 
highlighting a great need for improved therapeutic interventions 32. 
 
1.1.3 Malignant Melanoma 
Uncontrolled proliferation of melanocytes that are located in the basal layer of the epidermis 
can give rise to melanoma. The incidence of melanoma has increased drastically over the last 
half century, with a clear upwards trend in Australia, Europe and North America. Representing 
only five percent of all skin cancers, melanoma is classified as the most aggressive type of skin 
cancer with median survival times of 8-12 months and it accounts for most of skin cancer-
related deaths 33. If diagnosed early, simple surgery can resolve the problem. However, due to 
its aggressive nature melanoma usually spreads quickly to other organs, preferentially to the 
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lungs, liver and brain 34. Melanoma is often driven by mutations in signaling pathways 
controlling cell proliferation, growth, apoptosis and replicative lifespan of the cell. Thus, 
mutations in genes like BRAF, PTEN, P53 and TERT are commonly found in melanoma cells 
35. Furthermore, families carrying hereditary mutations in the CDKN2A gene have an increased 
risk of developing melanoma 36. CDKN2A is involved in the regulation of cell cycle 
progression through governing the G1 checkpoint and inducing stable p53 expression 37. As it 
is the case for breast cancer, Ki67 is used as a prognostic marker in melanoma to identify high 
cell proliferation, which correlates with the aggressiveness of the cancer 38. 
Previously, surgery and chemotherapy were the only treatment strategies for melanoma. Today, 
several targeted therapies are available for the treatment of melanoma. One of the most 
promising and frequently used strategy is to target BRAF in patients with BRAF mutations, 
using inhibitors such as vemurafenib 39. Additionally, immune check point inhibitors were 
found to have impressive effects regarding long-term survival, at least in a subset of patients, 
compared to other treatment options. The anti-CTLA-4 antibody ipilimumab and antibodies 
targeting the PD-1 receptor on T cells, such as pembrolizumab and nivolumab, are standard 
treatment of care and often used in combination to treat late stage melanoma 40. 
Even though these new types of therapies have led to significant improvements regarding 
overall survival, mortality rates are continuously rising. This is due to increasing numbers of 
cases as well as rapid development of resistance to therapies such as BRAF inhibitors 41,42, 
displaying the need for further research on melanoma. 
 
1.1.4 The Tumor Stroma 
Unlike one could believe, the tumor site not only consists of rapidly dividing tumor cells. 
Instead, the surrounding microenvironment of a tumor usually contains a complex mix of cell 
types of different origin (see Figure 4). Various cells of the innate and adaptive immune system 
can be found in the tumor microenvironment (TME), such as macrophages, dendritic cells, 
myeloid derived suppressor cells (MDSCs), NK cells, different subtypes of T cells and even B 
cells. Furthermore, endothelial cells and pericytes, that compose blood vessels and are essential 
for angiogenesis, make up an important part of the tumor stroma. Fibroblasts that get converted 
into cancer-associated fibroblasts (CAFs) which produce collagen fibers and aid in building up 
the extracellular matrix (ECM), are regular constituents of the tumor stroma 43.  
The majority of these cells are components of the normal tissue stroma with intrinsic anti-
tumoral capabilities, but are highjacked by the tumor cells to tolerate and even promote tumor 
growth. Other cells, such as most of the immune cells, get recruited to the tumor site by 
cytokines and chemokines released by the tumor and are then ‘educated’ by the suppressive 
environment to support tumor growth 44. The tumor stroma plays an essential role in tumor 
development and progression. The constant bilateral exchange of signals between tumor cells 
and cells of the tumor stroma allows for continuous growth and even invasion and metastasis 




Figure 4. The tumor microenvironment – host to a variety of stromal cells. 
 
 
Even though each single cell type represented in the tumor stroma is of importance for tumor 
progression, for the scope of this thesis only macrophages and natural killer cells will be further 
discussed in detail. 
 
1.1.5 Macrophages 
Macrophages belong to the innate branch of the immune system and are involved in a variety 
of processes assisting in keeping homeostasis in the body. Resident macrophages can be found 
in almost any tissue and are termed differently depending on their location (Langerhans cells 
in the skin, Kupffer cells in the liver, microglia in the brain or alveolar macrophages in the 
lung). On one hand, macrophages can originate from bone marrow-derived monocytes that 
circulate through the blood and get recruited to the tissue in case of infection or to replenish 
tissue-resident cells. On the other hand, tissue-resident macrophages can have their origin in 




During infection macrophages participate in the first line of defense. Macrophages possess a 
range of pattern recognition receptors (PRRs) that can recognize pathogen-associated 
molecular patterns (PAMPs) or danger-associated molecular patterns (DAMPs) that are 
intrinsic to pathogens and foreign particles. Upon activation, macrophages release different 
cytokines and proinflammatory mediators, reactive oxygen/ nitrogen species (ROS/ RNS) and 
antimicrobial peptides. As their name macrophage (Greek, “big eater”) suggests they can 
engulf pathogens by phagocytosis and lyse them inside phagolysosomes located in their 
cytoplasm 48. Macrophages can also act as antigen presenting cells via their MHC class I and 
II receptors, even though they do so less efficiently than dendritic cells 49. 
 
Macrophages show a high grade of plasticity, implying that they can easily change activation 
state depending on the factors they receive from their surroundings. Exposed to factors like 
interferon γ (IFN-γ), lipopolysaccharide (LPS) or granulocyte-macrophage colony stimulating 
factor (GM-CSF) they acquire a pro-inflammatory (classically activated) state which allows 
for stimulation of T cells. Surface markers that define this activation state include CD80, CD86 
and high expression of MHC class II. On the other hand, if factors like interleukin 4 (IL-4) and 
IL-13 prevail macrophages turn into an anti-inflammatory (alternatively activated) self which 
is crucial in tissue maintenance and wound healing 50. This activation state is accompanied by 
surface expression of markers such as CD206, CD163, and CD204 51,52. However, depending 
on their surrounding environment macrophages can adapt easily and acquire any stage in 
between these two extremes 53. Due to the great plasticity macrophages display there has been 
an ongoing discussion in the field how to uniformly define different macrophage populations 
and activation states 54. 
 
1.1.5.1 Tumor-associated macrophages 
Macrophages are present in the microenvironment of most cancers and usually constitute a 
critical mass of the tumor stroma 55. Importantly, high macrophage infiltration strongly 
correlates with poor patient survival 56,57. It has been shown that cancer cells express cytokines 
and chemokines (e.g. colony stimulating factor 1 (CSF-1) and C-C motif chemokine ligand 2 
(CCL2)) that attract bone marrow-derived monocytes from the blood into the tumor 
microenvironment where they mature into macrophages. These tumor-associated macrophages 
(TAMs) are exposed to distinct stimuli (IL-4, IL-10, transforming growth factor β (TGF-β)) 
released by the cancer cells favoring an anti-inflammatory and tumor-promoting state of these 
cells (see Figure 5) 58. TAMs, in return, initiate the secretion of pro-tumorigenic cytokines like 
IL-10, TGF-β and factors such as arginase 1 (Arg1), thereby promoting an immunosuppressive 
environment and the direct inhibition of cytotoxic T cells. Furthermore, they release factors 
including vascular endothelial growth factor A (VEGFA) and matrix metalloprotease 9 
(MMP9), which promote angiogenesis and result in an increased invasive behavior of the tumor 
cells 59. This type of heterotypical signaling between cancer cells and the surrounding stroma 




Figure 5. Plasticity of the activation state of macrophages and tumor promotion. 
 
Consistent with their great plastic potential, distinct subsets of TAMs can be encountered in 
different regions of the TME. Hypoxic areas are found to harbor TAMs with greater tumor-
promoting activity which were also defined to be more pro-angiogenic. As the tumor 
progresses these pro-tumoral TAMs get more abundant and overrule other, less tumor-
promoting, TAM populations 61. 
 
1.1.5.2 Targeting macrophages in cancer 
Due to the vast impact TAMs have on cancer progression, a lot of focus has been put on 
targeting macrophages in cancer. Several strategies have been tested, including complete 
depletion of macrophages, as well as shifting their activation state to a pro-inflammatory profile 
62. Listed below are some of the strategies currently tested in the clinics. 
 
Eliminating TAMs and blocking TAM recruitment 
Clodronate and Zoledronic acid are two small molecules belonging to the group of 
bisphosphonates. They have been shown to effect tumor growth directly and indirectly, by 
exerting apoptotic effects on macrophages, and are therefore currently investigated in clinical 
trials 63. Trabectedin is another small molecule that, besides its direct effects on tumor cells, 
was found to affect macrophage viability by inducing caspase 8 activation, thereby promoting 
apoptosis 64. 
Additionally, several studies have shown the effectiveness of targeting the CCL2/CCR2 or 
CSF/CSFR axis to inhibit TAM recruitment 65,66. However, at least when inhibiting CCL2, 
monocytes were retained in the bone marrow and released upon treatment cessation, resulting 




Repolarizing TAMs towards an anti-tumoral state 
Several strategies are currently investigated to repolarize TAMs into an anti-tumoral state. One 
of these strategies is using monoclonal antibodies against CD47, a protein commonly 
overexpressed by tumor cells, which binds to thrombospondin 1 and signal regulatory protein-
α (SIRPα) on macrophages and inhibits phagocytosis. Strikingly, CD47 blockage allows for 
macrophage-mediated destruction of tumor cells 68. Furthermore, agonists for toll-like 
receptors (TLRs) can be used to stimulate an anti-tumoral state in macrophages and were 
shown to have promising tumor-reducing effects 69.  
Macrophages also express CD40, a member of the TNF receptor family, which when activated 
promotes a pro-inflammatory state of the cells. Agonistic anti-CD40 antibodies were found to 
induce MHC expression on macrophages and result in tumor regression in mouse models 70. 
Another promising target is the MARCO receptor on macrophages, which when blocked leads 
to a switch in macrophage activation status and was shown to reduce tumor burden, especially 
when combined with checkpoint inhibitors 71. Furthermore, inhibition of the myeloid-specific 
PI3Kγ pathway induced expression of MHC class II as well as of pro-inflammatory cytokines. 
At the same time, it reduced expression of Arg1, the enzyme responsible for conversion of L-
arginine into ornithine and urea in TAMs. Importantly, low PI3Kγ activity correlated with 
enhanced patient survival 72. 
Alike T cells, TAMs express programmed cell death protein 1 (PD-1) 73. PD-1 is an example 
of an immune checkpoint receptor found on certain types of immune cells. Binding of its ligand 
PD-L1, which is commonly expressed by cancer cells, leads to immune tolerance and 
suppression of an anti-tumor immune response. Checkpoint blockade inhibitors are used to lift 
the negative regulation and instead promote an active anti-tumor immune response 74. 
Therefore, checkpoint blockade inhibitors might also be useful in targeting TAMs and improve 
T cell-dependent immunotherapies 73. 
 
1.1.5.3 TAMs in breast cancer 
As for many other cancer types, high infiltration of TAMs in breast cancer correlates with poor 
prognosis 75. In breast cancer, CD163 expression on TAMs was found to correlate with poor 
overall survival 76. TAM infiltration correlates with a worse prognosis also in the TNBC 
subtype. Additionally, presence of proliferating macrophages was linked to HR negativity and 
basal-like cancer 77,78. Furthermore, TAM infiltration was linked to higher chemoresistance in 
breast cancer 79.  
In human breast cancer at least two distinct types of TAMs have been identified, a migratory 
subtype, that promotes metastasis and shows expression of MHC class II, and a sessile subtype, 
that is tumor-promoting and expresses CD206 on its surface. The migratory TAM subtype was 
described to be located in perivascular areas, whereas the sessile TAMs were found in hypoxic 
areas and at the tumor-stroma border 80. Furthermore, a subtype of TAMs was identified which 
is associated with bone metastasis in breast cancer. These TAMs express high levels of CD204 
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and IL-4 receptor (IL4R). Upon blocking of IL4R outgrowth of bone metastasis was 
significantly reduced 81. Additionally, recently a subset of TAMs was described to express high 
levels of podoplanin which supports the binding to lymphatic vessels and promotes 
lymphoinvasion in breast cancer 82. Clearly, distinct subsets of TAMs exist in breast cancer and 
identification of their functions is necessary for the development of macrophage-targeted 
treatment strategies.  
 
1.1.6 Natural killer cells 
Like macrophages, natural killer (NK) cells belong to the innate immune system. However, 
their mode of action is entirely different. NK cells are able to recognize body-own infected, 
stressed or transformed cells and eliminate them without the need for prior priming, as it is the 
case for T and B lymphocytes of the adaptive immune system 83.  
Compared to other cell types of the immune system, NK cells were discovered rather late, in 
1975 84. How NK cells are able to distinguish between healthy and infected cells was proposed 
a few years later. It was concluded that NK cells must detect receptors on the surface of body-
own cells which would inhibit them to get activated. These receptors were identified to be 
human leukocyte antigen (HLA) molecules. Loss or alteration of HLA expression upon 
infection or transformation of cells allows for the initiation of a NK cell response. This was 
termed the missing-self-hypothesis 85,86.  
Nowadays, we know that NK cells display a multitude of activating and inhibiting receptors 
on their cell surface and NK cell activation is regulated by the balance of all incoming stimuli. 
Upon activation, NK cells degranulate and release granzyme B and perforin into the 
surroundings, damaging target cells and forcing them to undergo apoptosis 87. NK cells can 
also release cytokines and chemokines, such as IFN-γ, tumor necrosis factor α (TNF-α) and 
CCL5, to stimulate an immunological response, recruiting additional immune cells to the site 
of infection 88.  
 
Inhibitory NK cell receptors: 
Inhibitory NK cell receptors are fundamental for the tolerance of healthy cells of the body. 
These types of receptors recognize HLA class I molecules that are present on the surface of all 
cells of the body. During their development NK cells undergo an ‘educational’ process and get 
eradicated if they falsely get activated by body-own cells to prevent the development of 
autoimmune diseases. A group of well-studied inhibitory receptors on NK cells are the killer-
cell immunoglobulin-like receptors (KIRs) which recognize HLA-A, B and C molecules 89. 
Another inhibitory receptor on NK cells consists of the heterodimer NKG2A/CD94 and 





Activating NK cell receptors: 
Activating NK cell receptors are essential for detecting unhealthy cells, such as stressed or 
infected cells, which often upregulate specific ‘stress’ ligands on their surface. One of the most 
studied activating receptors on NK cells is the NKG2D receptor. NKG2D signals as a 
homodimer and has eight different ligands which are all MHC class I related molecules. In 
humans these include MICA, MICB and UL binding protein 1-6 (ULBP1-6) 91. Another group 
of major NK cell activating receptors comprises natural cytotoxic receptors (NCRs), NKp46 
(NCR1), NKp44 (NCR2) and NKp30 (NCR3). NKG2C is one more example of an activating 
NK cell receptor. Competing with NKG2A it also binds to HLA-E, however with lower affinity 
92. The surface receptor CD16 on NK cells also acts as an activating receptor by binding the Fc 
part of antibodies and inducing antibody-dependent killing by NK cells 93. Finally, besides 
inhibitory KIRs, also a group of activating KIRs can be found on NK cells 89.  
 
 
 Figure 6. Interaction of NK cells with target cells 
 
As mentioned previously, a fine balance of the stimulation of inhibitory and activating 
receptors determines the fate of the NK cells, either getting activated to fight or staying neutral 
and tolerate (see Figure 6) 94.  
In humans, NK cells derive mainly from progenitors in the bone marrow and make up 10-15% 
of mononuclear cells in the blood. They are commonly defined as CD3-CD56+ and can be 
further divided by the extent of CD56 expression. The majority of NK cells is CD56 dim which 
concurs with greater ability to kill target cells and goes along with the expression of the surface 
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receptor CD16. CD56 bright NK cells are considered to be active cytokine producers and less 
efficient in target cell killing and show no or dim CD16 surface expression 95. 
Circulating NK cells in the blood are usually in a resting state but can be activated by cytokines 
such as, interleukin 2 (IL-2) and interleukin 15 (IL-15), which are typically released at sites of 
infection or neoplastic growth. Activation by IL-2 or IL-15 promotes differentiation and 
proliferation of NK cells and enables production of perforin and granzyme B 96. Even though 
IL-2 and IL-15 use similar IL2 receptor units, IL-15 has been shown to be a stronger activator 
of NK cells, rendering them more resistant to inhibition by oxidative stress 97,98. 
Normally, upon activation NK cells are short lived. They perform their task, killing target cells, 
until they get exhausted and undergo apoptosis.  
 
1.1.6.1 NK cells in cancer 
As mentioned above, NK cells have the intrinsic ability to detect transformed cells 83. They are 
therefore believed to exert an important role in immunosurveillance by detecting and 
eliminating tumor cells at an early stage. However, in the progression of tumor development 
they become overwhelmed by the immunosuppressive milieu. Interestingly, the NK cell 
population in non-small cell lung cancer was found to be enriched in cytokine producing CD56 
bright NK cells and these NK cells were found to have a lower capacity of killing tumor cells 
99. Nonetheless, high NK cell infiltration has been associated with better clinical outcome in 
several types of cancer 100-102. 
NK cell function is often compromised dramatically by tumor-promoting cell types. TAM or 
neutrophil derived arginase I-dependent depletion of L-arginine reduces NK cell proliferation 
and diminishes IFN-γ production by NK cells 103. Furthermore, TAMs and MDSCs impair NK 
cell function by releasing immunosuppressive cytokines such as IL-10, prostaglandin E2 
(PGE2) and TGF-β, which reduce NK cell activation and additionally attract more immune 
suppressive cell types like regulatory T cells (Tregs) 104.  Tregs are capable of directly inhibiting 
NK cells by surface expression of TGF-β which was found to induce downregulation of the 
NKG2D receptor on NK cells 105.  
Furthermore, a regulatory NK cell phenotype has been identified. These regulatory NK cells 
were shown to release anti-inflammatory cytokines, IL-10 and IL-13, while also producing pro-
inflammatory cytokines belonging to their normal repertoire (IFN-γ, TNF-α). These additional 
cytokines were sufficient to shift the balance and inhibit not only dendritic cells and 
macrophages, but also T cells 106,107. The exact role of regulatory NK cells still needs to be 
precisely defined. 
Tumor cells often present aberrant expression of NK cell receptor ligands on their surface. One 
example are the ligands for NKG2D that are commonly upregulated on transformed cells as an 
indication of stress and NKG2D has been shown to be an important mediator of cancer 
immunosurveillance 108. Cancer cells, however, have developed ways to overcome this 
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mechanism by shedding NKG2D ligands. On one hand, this prevents NK cell killing as no 
activating ligand is detected. On the other hand, it also impairs NKG2D expression on NK and 
T cells as a result of continuous receptor stimulation 109.  
In addition, MHC class I receptors are often downregulated by cancer cells to overcome 
immunosurveillance by T cells 110. Even though, theoretically, NK cells should get activated 
upon recognizing these tumor cells they were found to exist in an anergic state in MHC class 
I-deficient tumors 111, proving the effective strategies of cancer cells to overcome immune 
surveillance. 
NK cells have recently moved into the spotlight of attention for their use as immunotherapies 
of different cancers. Especially different types of hematopoietic cancers benefited from NK 
cell-based immunotherapies 112,113. 
 
1.1.6.2 NK cells in breast cancer 
As mentioned previously, infiltration of NK cells into the tumor microenvironment correlates 
with better survival in breast cancer patients 100. Furthermore, breast cancer patients with high 
expression of NKG2D ligands, MICA/B and ULBP2, had improved outcome with increased 
relapse-free periods 114. However, natural killer activity of peripheral blood mononuclear cells 
was significantly reduced in patients with breast cancer, suggesting suppressed NK cell 
function in cancer 115.  
Nonetheless, NK cells are important contributors to current treatment strategies for breast 
cancer. NK cells were shown to infiltrate the TME after treatment with HER2-targeted 
therapies. Actually, these NK cells actively contribute to the anti-tumor effects of the HER2 
antibody treatment through their ability of antibody-mediated cellular cytotoxicity (ADCC) 116. 
In TNBC, an antibody targeting epidermal growth factor receptor (EGFR), which is often 
upregulated in basal breast cancer, has been described to elicit ADCC mediated by NK cells 
117. Taken together, NK cells as well as NK cell ligands on cancer cells play a critical role in 
immune evasion and treatment strategies in breast cancer. 
 
1.1.7 Inflammation and cancer 
In 1863, the German physician Rudolf Virchow noted infiltration of leukocytes into the tumor 
site and made a first connection between cancer and inflammation 118. Since then the 
consequences of inflammatory processes have been described in detail, from the initial steps 
of tumor development up to its influence on metastatic growth. Importantly though, several 







Acute inflammation is the normal reaction of the body’s immune system to a potential threat 
to the body. Immune cells get recruited to the site which produce inflammatory cytokines and 
release ROS into the environment to kill the intruder. In case of cancer, acute inflammation is 
a desired process. Activated immune cells have the ability to recognize and kill cancer cells 
and potentially resolve the issue. In fact, most pre-cancerous lesions are detected by the 
immune system and eliminated before any damage has been made to the body, which has been 
termed cancer immunosurveillance 120.  
 
Extrinsic chronic inflammation 
If the immune system fails to clear the initial threat this can lead to chronic inflammation, which 
leaves a constantly activated immune system localized to a specific organ/site. The continuous 
release of inflammatory signals as well as factors such as ROS can result in damage to the 
tissue and induce mutations in surrounding cells. Furthermore, the release of growth signals 
can promote abnormal cellular growth. There are several examples where chronic 
inflammation is linked to cancer development. Infection with Helicobacter pylori has been 
correlated with increased risk of developing gastric cancer 121. Human papilloma virus (HPV) 
has been linked to cervical cancer and viruses of the hepatitis family can cause hepatocellular 
carcinomas  122,123. As these examples indicate, extrinsic chronic inflammation is caused by 
factors extrinsic to the cancer cells. 
 
Intrinsic chronic inflammation 
Intrinsic chronic inflammation, on the other hand, indicates that the stimulus underlying the 
chronic inflammation originates from the cancer cell itself. During the process of a cell 
becoming cancerogenic mutations occur that can affect the interaction with the immune system, 
such as oncogene-driven production of inflammatory signals. This continuous release of 
inflammatory factors leads to the recruitment and infiltration of immune cells and the 
establishment of a chronic inflammation 124.  
 
The concept of immunoediting includes three stages of tumor-immune system interaction. 
Elimination, which involves acute inflammation and the potential complete eradication of the 
tumor. A state of equilibrium, where the immune system is fighting the cancer, but the tumor 
cells are continuously proliferating and mutating. And finally, escape, where some clones 
manage to evade the detection of the immune system and start to edit the immune system for 
its benefits 120.  
Chronic inflammation, either intrinsic or extrinsic, is considered favorable for tumor growth 
due to the continuous selection of tumor cell clones able to escape recognition and elimination 
by the immune system. Additionally, as discussed above in the chapter ‘The Tumor Stroma’, 
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immune cells recruited into the TME are educated by the tumor to support it with growth 
factors, prevent it from being attacked by the immune system and facilitate invasion and 
metastasis 44. Currently, researchers are investigating strategies to shift the inflammatory 
profile away from a chronic and more to an acute stage, where immune cells are released from 
their inhibitions and are able to exert their anti-tumoral potential. Immunotherapies, such as 
checkpoint therapies, are developed on this underlying principle 125.  
Intriguingly, TAMs are firmly engaged in the relationship between cancer and inflammation. 
By secreting pro-tumoral cytokines they are actively shaping an immunosuppressive 
environment 59.  
 
1.1.8 The NF-κB Pathway 
The NF-κB pathway is known as the master regulator of inflammation since it is involved in 
the regulation of almost all processes related to inflammation. This pathway comprises a key 
family of transcription factors, which can form several different homo- and heterodimers. The 
NF-κB family consists of p65 (RELA), p105 /p50 (NFkB1), p100/p52 (NFkB2), RelB (RELB) 
and c-Rel (REL). 
  
 
Figure 7. The NF-κB pathway, its activators and targets. 
 
 17 
A multitude of stimuli can lead to the activation of the NF-κB pathway that can be divided into 
a classical (canonical) and an alternative (noncanonical) pathway (see Figure 7). Stimuli 
include viral and bacterial proteins, DNA damage, oxidative-stress, necrotic bi-products, or 
pro-inflammatory cytokines. The most common ligands for the classical NF-κB pathway are 
LPS, TNF-α and IL-1. Upon binding of the ligand to the receptor the IKK kinase complex gets 
phosphorylated and in turn induces the phosphorylation of IκB, which then gets ubiquitinated 
and degraded. IκB is usually bound to p65 and retains it in the cytoplasm of the cells. However, 
upon its degradation p65/p50 is released and can translocate into the nucleus where it binds to 
its target genes and initiate their transcription 126.  
The alternative pathway, on the other hand, gets activated by specific ligands that belong to the 
TNF superfamily such as CD40 and RANKL. The alternative pathway acts slower than the 
classical pathway and mainly relies on p52/RelB heterodimers for transcriptional activity 127. 
Depending on the stimulus and on its binding partners NF-κB can activate the expression of 
different groups of target genes, which can belong to cytokines and chemokines, proliferation 
signals, anti-apoptotic factors, angiogenic regulators or matrix metalloproteinases 128. 
 
1.1.8.1 NF-κB in cancer 
The NF-κB pathway plays a bit of a dual role in cancer. On one hand, it is fundamental for pro-
inflammatory processes and essential for anti-tumoral functions of immune cells 129,130. On the 
other hand, NF-κB activation in cancer cells promotes their survival and proliferation, while 
suppressing apoptosis. Besides that, NF-κB induces chronic inflammation promoting a tumor-
supporting microenvironment and has been reported to influence epithelial-to-mesenchymal 
transition (EMT), invasion and metastasis, as well as angiogenesis. It has also been found to 
contribute to therapy resistance. For these reasons, it is well established that activation of the 
NF-κB pathway is heavily involved in cancer development and progression 131.  
 
1.1.9 Hypoxia 
Hypoxia is defined as reduced oxygen levels compared to the regular state. Oxygen levels vary 
greatly within the body, however, on average physiological oxygen levels in tissues lie around 
five percent 132. Hypoxic regions can be found in most solid tumors due to rapid and 
uncontrolled cell growth. Inflammation also contributes to hypoxia because of increased 
metabolic activity and infiltration of immune cells  that contribute to increased cellular density 
in the tissue 133.   
Under normal conditions, e.g. the presence of sufficient oxygen, oxygen sensing prolyl 
hydroxylases (PHDs) drive the hydroxylation of a group of hypoxia inducible factors (HIF-1α, 
HIF-2α and HIF-3α; in this thesis the focus will be on HIF-1α). This hydroxylation allows then 
binding of the von Hippel-Lindau (VHL) protein to HIF-1α which consequently results in the 
polyubiquitination of HIF-1α by an E3 ligase complex that consists of Rbx1, Cullin 2, Elongin 
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B and Elongin C (ECV complex) 134. The polyubiquitination by the ECV complex leaves HIF-
1α as a target for rapid degradation by the proteasome (see Figure 8) 135.  
In case of a hypoxic environment the PHD enzymes cannot exert their function, which results 
in increased stability of HIF-1α and can therefore enter the nucleus where it dimerizes with its 
co-factor HIF-1β, binds hypoxia responsive elements (HREs) and activates transcription of its 
target genes.  
 
 
Figure 8. The HIF-1α pathway under normal or low oxygen conditions. 
 
HIF-1α acts as a major transcription factor regulating numerous genes involved in 
angiogenesis, such as VEGF. Besides that, HIF-1α has been reported to transcribe genes 
relevant in EMT, metastasis and chemo- and radio-resistance 136. Hypoxia also exerts an impact 
on immune cells in the tumor microenvironment, promoting the suppressive functions of tumor 
associated macrophages and regulatory T cells 137,138. Interestingly, hypoxia also affects 
inflammation and several reports highlight a dynamic crosstalk between the hypoxia pathway 
and the NF-κB pathway 139-141. Importantly, hypoxia and hypoxic gene expression is usually 
associated with poor patient survival 142. 
 
1.1.10 Angiogenesis 
Unavoidably, the continuous, uncontrolled growth of tumor cells reaches a point where oxygen 
and nutrition levels are insufficient for cellular survival and where waste products cannot be 
cleared from the TME. As discussed in the previous section (‘Hypoxia’), low oxygen levels 
drive the expression of an adaptational cellular program to overcome these obstacles by 
inducing angiogenesis. This point is referred to as angiogenic switch and is essential for 
advanced tumor growth 143. Angiogenesis is the process of blood vessel formation by 
endothelial cells. Blood vessels are comprised of endothelial cells and covered by pericytes, 
which are stromal cells that give structural support to the vessels. Upon pro-angiogenic cues 
 
 19 
like VEGFA (or VEGFC, which induces lymph vessel formation), VEGFR2 gets activated on 
endothelial tip cells which induces sprouting and proliferation of the cells. Endothelial tip cells 
migrate towards the cytokine gradient followed by stalk cells extending the sprout and forming 
the lumen. Platelet-derived growth factor B (PDGFB) is expressed by sprouting endothelial 
cells and leads to the recruitment of pericytes to stabilize vessel formation. Sprouting and 
branching of the vessels continues until an organized network has been constructed to support 
the tissue with sufficient oxygen 144. 
In cancer, angiogenesis is needed for oxygen supply and the transportation of nutrients to as 
well as waste products from the tumor 143. However, unlike angiogenesis in healthy tissues, in 
tumors this process is less strictly regulated resulting in unorganized and leaky blood vessel 
formation. This prevalent leakiness increases vessel permeability and the ease of cell migration, 
hence, increasing the metastatic potential of the tumor 145. As mentioned earlier (see section 
‘Tumor associated macrophages’), TAMs play a significant role in tumor angiogenesis. TAMs 
as well as tumor cells in hypoxic areas induce the expression of VEGF which drives the process 
of angiogenesis. Furthermore, by expressing MMPs, TAMs are able to remodel the 
extracellular matrix to create space for vessel formation 146.  
Angiogenesis correlates with poor survival in many cancer types and multiple strategies to 
target this process have therefore been investigated 147-149. Several drugs have been approved 
as anti-angiogenic therapy, most of them targeting members of the VEGF family. However, 
side effects and the fact that tumor cells manage to become resistant and escape therapeutic 
intervention has so far limited feasible treatment strategies 150. 
 
1.1.11 Multidrug Resistance in Cancer 
There are plenty of drugs against cancer available on the market and often they show tumor-
reducing effects at first. However, tumors are extremely heterogeneous. Clonal heterogeneity 
exists intra-tumoral, within the primary tumor, as well as between primary tumor and metastatic 
lesions, due to a constant turnover and mutational load, but it is also caused by therapeutic 
pressure 151. Often a single drug is effectively killing most of the tumor cells resulting in 
remission. However, a few clones might be able to survive the treatment and allow regrowth 
of the tumor 152. To overcome single drug resistances physicians started treating cancer patients 
with combinations of chemotherapies with different modes of action, which helped to reduce 
drug resistances. Even though combinational therapies showed greater effects than single 
treatments efficiency plateaued at some point. Also, against more recent cancer therapies, such 
as targeted therapies and immune checkpoint therapies, cancer cells have been shown to 
develop resistance 153.  
In case of chemotherapy tumor cells have been described to utilize different ways to evade 
killing. One frequent mechanism involves the upregulation of specific proteins located in the 
cell membrane that act as transporters for various molecules to pump them out of the cell. The 
largest group of these transporters is the ATP-binding cassette (ABC) family, many of which 
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members are often found to be upregulated in different cancer types, including breast cancer 
154,155. (This will be discussed in more detail in the results and discussion part of Paper IV). 
Strikingly, it seems tumor cells have an extreme ability to adapt, in order to ensure their 
survival. It is therefore a huge challenge to overcome multidrug resistance in cancer, which, if 
ever resolved, will save millions of lives.   
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1.2 P73  
1.2.1 Part of the p53 Family 
TP73 is a gene that is part of the p53 family together with TP53 and TP63. TP53 is the most 
studied tumor suppressor gene existing to date 10. The proteins of p53, p63 and p73 function as 
transcription factors for a variety of target genes including players fundamental in the 
regulation of cell cycle arrest and apoptosis such as p21 and Bax, as well as MDM2 that is the 
main negative regulator of p53 stability 156. Activation of the members of the p53 family can 
be induced by multiple internal and external stimuli. These include DNA damage, hypoxia, 
NTP depletion and oncogene activation among others 157. All members of the p53 family share 
both structural and functional homology. In general, the protein structure contains a 
transactivation domain (TAD), a DNA binding domain (DBD) as well as an oligomerization 
domain (OD). All three family members contain proline rich sequences (PR), but only the p63 
and the p73 gene contain a sterile alpha motive domain (SAM) at the C terminus (see Figure 
9). Proteins of the p53 family can form tetramers of homo-complexes, in the case of p53, or 
hetero-complexes, p63 and p73, and can bind to the same DNA sequences since they share 
100% homology in the residues interacting directly with DNA 158,159.  
 
 
Figure 9. Structural similarities within the p53 protein family.   
(Percentages indicate structural homology with p53.) 
 
The cellular availability of p53 family members is tightly regulated at a post-translational level 
by ubiquitination. MDM2 is the best studied E3 ubiquitin ligase found to modulate the 
transcriptional activity of p53, p63 and p73 160. Due to its crucial regulation of p53 activity, 
MDM2 has been termed the gatekeeper of p53. Under normal conditions MDM2 binds to p53 
and ubiquitinates it, which leads to p53’s proteasomal degradation. Furthermore, MDM2 can 
also bind to the TAD of all proteins of the p53 family, thereby inhibiting their transcriptional 
activity 161. On top of that, a recent study suggests the involvement of MDM2 in ubiquitination 
and proteasomal degradation of p73 162. Upon cellular stress p53 gets phosphorylated at Ser15 
by stress-induced kinases (ATM, ATR, c-Abl), which disables binding of MDM2, thus 
allowing for protein stability 163. Additionally, MDM2 levels are reduced upon stress signals 
which releases the inhibition on p53 and the other family members 164. In turn, MDM2 
expression was shown to be partly regulated by p53 family members, indicating an 
autoregulatory feedback loop on p53 activation 165. An important regulator of p73 proteins is 
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the ubiquitin-protein ligase Itch. P73, as well as p63, have been reported to bind Itch, which 
leads to their proteasomal degradation 166,167. Upon DNA damage, Itch is downregulated which 
lifts Itch-mediated degradation and allows for accumulation of p73 and p63 proteins. 
Opposingly, YAP-1 (Yes-associated protein 1) binds the same region of p73 as Itch and thereby 
interferes with Itch-dependent p73 degradation 168. While so far it is unknown if YAP-1 also 
effects p63, p53 was shown to be unaffected.  
Even though several common target genes of the p53 family have been confirmed, the 
individual members were found to play unique roles in regulating various processes during 
embryonic as well as tumor development 169,170. These differences are thought to be due to 




The TP53 gene has been described the first time in 1979 and since then has become one of the 
most studied genes in cancer 171. This is due to the fact that the TP53 gene is found mutated in 
around thirty to fifty percent of all cancers, being the most frequently mutated gene so far 
described in the cancer genome 172. When not functionally inactivated by mutations, some 
mutant p53 variants were found to display gain-of-function properties 173. Actually, when p53 
was discovered it was thought to be an oncogene and it took the scientific community several 
years to agree upon p53 being a tumor suppressor 174. Since then p53 is commonly referred to 
as ‘the guardian of the genome’ being able to induce cell cycle arrest, DNA repair or apoptosis 
in response to potential oncogenic events 175.  
Importantly, several viral proteins have the ability to interfere with the functions of wildtype 
p53, including the Simian Vacuolating Virus 40 (SV40) large T-antigen protein, which was 
shown to bind p53 and thereby prevent p53-mediated transcription of pro-apoptotic genes 176. 
Additionally, the E6 protein, which is found in HPV, is able to bind p53 and promotes its 
proteasomal degradation by an E3 ligase 177. Furthermore, also E7, another viral protein of 
HPV, has been described to interfere with p53-dependent cell cycle control 178. Yet, another 
mechanism to inhibit p53-mediated transcription has been described for the mouse polyoma 
virus. Polyoma virus proteins seem to interfere with p53 activation by disrupting upstream ARF 
signaling 179.  
In line with the frequent inactivation of p53 in cancers, p53 knockout mice were shown to be 
prone to develop lymphomas and sarcomas at around six months of age.  However, most 
animals deficient for p53 do not show any indication of developmental deficiencies 180. (Of 







Contrary to p53 knockout mice, mice deficient for p63 die within a day from birth, showing 
evident malformations. They display severe defects in the establishment of stratified epithelium 
which causes abnormalities in limb and craniofacial development 182. These findings revealed 
an important role for p63 in the maintenance of epithelial precursor cells. 
Besides its function in epidermal regulation, p63 has also been described to play a role in 
progression of various cancers, including hepatocellular carcinoma and squamous cell 
carcinoma 183-186. TP63 and TP73 share similar gene structures, leading to various tumor-
suppressing and oncogenic protein isoforms with opposing functions on tumor development 
(see following section) 187. 
 
P73 
P73 was first discovered in 1997, almost 20 years after its family member p53. The TP73 gene 
is located on the chromosome 1p36 and is thought be expressed mono-allelic 188. This region 
of chromosome 1 is often lost in cancer, including neuroblastoma 189.  
TP73 can be transcribed from two distinct promoters 190,191. Transcription from the proximal 
P1 promoter gives rise to the full-length protein which acts as a tumor suppressor in a similar 
fashion as p53. This full-length protein is called TAp73 since it contains the transactivation 
domain. Transcription from an alternative internal P2 promoter, however, leads to a N-
terminally truncated version of p73 that is missing the transactivation domain. This protein has 
been termed ΔNp73 and acts as a dominant negative. To increase complexity, alternative 
splicing of the pre-mRNA leads to various additional C-terminal isoforms, termed α-η, and the 
splice variants p73ΔEx2 and p73ΔEx2/3 in the N-terminal region (see Figure 8) 192.  
 
  




P73 deficient mice are viable but show eminent mortality rates at young age. These mice 
present severe defects in the neurological development of the central nervous system as well 
as hypoplasia of the olfactory bulb and 100% penetrance of severe hydrocephalus 193,194.  
Additionally, p73 knockout mice present severe chronic airway infections 194. Surprisingly, 
neither p63 nor p73 knockout mice show a clear predisposition for spontaneous tumor 
development. However, mice heterozygous for both p63 and p73 but with wild type p53 exhibit 
reduced survival due to the development of various tumor types manifesting the importance of 
functional p63 and p73 in tumor development independent of p53 195.  
Isoform specific knockout mice were needed to investigate the impact of TAp73 and ΔNp73 
individually. Mice deficient for TAp73 present defects in hippocampal development as well as 
in maintenance of genomic stability. Furthermore, these mice display chronic respiratory tract 
infections, which were discovered to be due to severe defects in the process of 
multiciliogenesis. Actually, recently TAp73 was shown to play a profound role as 
transcriptional regulator in multiciliated cells 196,197. TAp73 knockout mice are infertile and 
show an increased rate of spontaneous as well as carcinogen-induced tumor development 198. 
These findings confirm the importance of TAp73 as a tumor suppressor.  
In contrast, ΔNp73 knockout mice are fertile and show a normal life span but present some 
degree of neurodegeneration. ΔNp73-/- cells exhibit increased p53 target gene expression at 
steady state levels and even higher after DNA damage which confirms the notion that ΔNp73 
usually inhibits the function of p53. As could be suspected, transformed ΔNp73-/- cells show a 
drastically reduced ability to form tumors upon injection into immunocompromised recipient 
mice 199. Hence, this furthermore confirms ΔNp73s action as an oncogene. Taken together, 
these findings highlight the importance of studying specific p73 isoforms rather than looking 
at total p73 levels. 
 
1.2.2 P73 in Cancer 
Interestingly, TP73 is rarely mutated in cancer. Instead it is thought that there is a shift in 
balance between the expression of the two isoform groups, TAp73 and ΔNp73 200. This leaves 
p73 as an exception to the standard Knudson tumor suppressor, since TAp73 gene expression 
does not have to be lost in order to overcome its tumor suppressing functions. Since ΔNp73 
binds the same DNA binding motifs as TAp73, p53 and p63 it can compete for binding to the 
DNA and thereby inhibit transcription. Furthermore, it can form hetero complexes with TAp73 
but also with p63 and thereby actively inhibit their function 190,201. Additionally, studies have 
revealed that wild type and mutant p53 can bind p73 after JNK-mediated phosphorylation of 
Thr81 in the DBD of p53. This leads to structural changes that increase affinity, thereby 
enhancing wildtype p53’s function of promoting pro-apoptotic gene expression 202. 
Consequently, it seems that cell fate is dependent on the delicate balance and the complex 
interactions of all the members of the p53 family. 
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The significance of p73 expression in tumor tissue has been validated in several studies using 
patient data with the conclusion that upregulation of total p73 protein is correlated with poor 
prognosis in various cancers including colorectal adenocarcinoma, hepatocellular carcinoma 
and lung cancer 203-205. However, when looking at specific isoforms, ΔNp73 can be found 
upregulated in multiple types of carcinoma and is correlated with poor prognosis in 
neuroblastic tumors, colon and breast cancer as well as gynecological cancers 201,206-208. 
Intriguingly, in many cancers both TAp73 and ΔNp73 are upregulated, however, the outcome 
seems to depend on the balance between the isoforms 209. In contrast to carcinomas, in a number 
of leukemias and lymphomas the P1 promoter, responsible for expression of the full-length 
isoform TAp73, is hypermethylated which results in inhibition of expression and, 
consequently, loss of TAp73 function 210.  
Importantly, increased TAp73 expression has been described to be induced by 
chemotherapeutic drugs in p53 mutant tumor cells. Concurrently, TAp73 inhibition resulted in 
chemo-resistance in tumor cells regardless of their p53 status 211. Overall, it can be concluded 
that p73 has been identified as a promising biomarker for prognosis of cancer patients 
especially when dissecting the individual isoforms. 
 
1.2.2.1 P73 in Breast Cancer 
Both tumor-suppressing and tumor-promoting p73 isoforms are commonly found to be 
upregulated in breast cancer. However, only upregulation of ΔNp73 has been found to correlate 
with worse prognosis in breast cancer patients 207. TP73 expression can be regulated by 
epigenetic changes in promoter methylation. A recent study describes the frequent methylation 
of CpG islands in the TP73 promoter in breast cancer with varying intensity within different 
molecular subtypes. Within this study, the expression of ΔNp73 was found to correlate with 
higher histological grade of the tumor and showed a trend towards worse overall survival in 
invasive ductal carcinoma 212. The DNA demethylation agent 5-aza-2'-deoxycytidine was 
found to promote upregulation of TAp73, while downregulating ΔNp73, and thereby resulting 
in enhanced cell cycle arrest and induction of apoptosis 213. 
The inactivation of p53 in various breast cancer cell lines led to the increased expression of 
TAp73 mediated through the transcription factor E2F-1, indicating an intrinsic rescue 
mechanism in the cells 214. Furthermore, in p53 deficient breast cancer cell lines TAp73 was 
shown to take over induction of cell cycle arrest and apoptosis in response to chemotherapeutic 
drugs 215.  
Overall, it can be concluded that p73 isoforms seem to play a significant role in the progression 




1.2.2.2 P73 in Melanoma 
While in other cancers ΔNp73 is often upregulated and associated with worse survival, in case 
of melanoma ΔNp73 levels were described to be unchanged. Instead the oncogenic p73 
member p73Δex2/3 was described to be upregulated in melanoma and especially in invasive 
melanoma 216. This isoform is transcribed from the P1 promotor of the TP73 gene, but due to 
alternative splicing in exon 2 and 3 it is missing the transactivation domain and consequently 
acts as a dominant negative, comparable to ΔNp73 217. In melanoma the simultaneous 
upregulation of p73Δex2/3 and TAp73 was detected to be regulated by E2F-1-mediated 
transcription from the P1 promoter 216. Furthermore, p73Δex2/3 was found to promote the 
expression of genes involved in stemness and depletion of p73Δex2/3 reduced metastasis in 






2 AIMS OF THE THESIS 
 
The overall aim of this thesis is to understand the specific functions different p73 isoforms 
exert in regulating the tumor microenvironment, with a strong focus on breast cancer. 
 
Specific aims of the studies included in this thesis: 
 
Study I: To investigate how TAp73 influences macrophage infiltration and phenotype in breast 
cancer. 
 
Study II: To get an insight if ΔNp73 is involved in the regulation of NK cell ligands and its 
effects in breast cancer. 
 
Study III: To unravel the role of ΔNp73 in hypoxia regulation – using breast cancer as a model. 
 






3 RESULTS AND DISCUSSION 
 
3.1 PAPER I 
 
TAp73 represses NF-κB-mediated recruitment of tumor-associated macrophages in 
breast cancer. 
 
Up to date there is little information if and how different p73 isoforms regulate immune cells 
in cancer. In a recent publication we identified TAp73 as an important regulator of pro-
angiogenic factors in breast cancer 219. Many of these angiogenic activators are also involved 
in the recruitment of immune cells. We were therefore curious to investigate if TAp73 plays a 
role in immune cell recruitment in breast cancer.  
To follow up on our previous findings, we used the publicly available TCGA breast cancer data 
set and compared TAp73 low and high expressing samples, while removing all samples 
showing expression of the oncogenic isoform, ΔNp73, to exclude possible reciprocal 
interactions. Gene set enrichment analysis and consequent pathway analysis displayed a 
substantial correlation between low TAp73 expression and a strong inflammatory signature in 
breast cancer biopsies. Furthermore, several gene sets enriched in low TAp73 samples were 
tightly linked to an increased NF-κB signature. Using TAp73 deficient cells we observed that 
loss of TAp73 resulted in higher activity of the NF-κB pathway, confirming our observations 
in human breast cancer patients. 
Inflammation and an active NF-κB pathway are strongly linked to tumor progression and 
metastasis, as described in the chapters ‘Inflammation in cancer’ and ‘NF-κB in cancer’. While 
not so much information is available for different p73 isoforms, several studies describe the 
interaction of p53 and the NF-κB pathway. P53 was found to repress the NF-κB pathway and 
concomitant pro-inflammatory cytokine release by interfering with IκB degradation via 
diminished proteasome activity 220,221. In contrast, accumulation of mutant p53 was found to 
correlate with increased NF-κB activation in human colon cancer 222. Mutant p53 was 
furthermore shown to induce transcription of NF-κB2, supporting proliferation and motility of 
the cells 223. Clearly, there is a bilateral interplay between NF-κB and p53, and depending on 
the ratio, this either results in NF-κB inhibition by p53 or otherwise inhibition of p53 by 
members of the NF-κB pathway. NF-κB and p53 were shown to compete for the same 
transcriptional co-activator, p300/CBP (CREB-binding protein) 224-226. Also p63 was shown to 
interact with p300/CBP to regulate transcription of target genes, such as p21 227. 
Intriguingly, just like the other family members, p73 isoforms were found to interplay with the 
NF-κB pathway. IkappaB kinase beta (IKKβ) has been described to promote cell survival 
through inhibiting p53 functions by phosphorylating and stabilizing ΔNp73α 228. Furthermore, 
TAp73 has been found to compete with the NF-κB subunit p65 for binding to p300/CBP 229,230. 
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This reciprocal competition for the transcriptional co-activator might be the underlying 
mechanism how TAp73 inhibits the expression of the NF-κB-dependent production of pro-
inflammatory cytokines that we describe here.  
To validate the upregulation of proinflammatory factors detected in TAp73 deficient tumors 
we analyzed mRNA expression and secretion levels of several cytokines and chemokines in 
wildtype and TAp73 knockout cells. This left us with CCL2 showing the highest upregulation 
both on mRNA levels as well as in protein secretion in TAp73 deficient cells. We confirmed 
the downregulation of CCL2 upon overexpression of TAp73 in several murine and human 
breast cancer cell lines. Interestingly, the TAp73β isoform, but not TAp73α, led to a reduction 
in CCL2 levels. Several studies have shown the different effects TAp73α and TAp73β have on 
target gene expression, with TAp73β comprising stronger transcriptional activity 231. It is 
suggested that this stems from their structural differences as TAp73α contains a SAM domain 
in its C-terminal region 232. This SAM domain has been shown to exert inhibitory functions on 
TAp73α ability to transcribe target genes. In line with this, the C-terminal region, including the 
SAM domain, has been described to inhibit interaction with the co-transcriptional activator 
p300/CBP, thereby suppressing transcription of target genes 233.  
While overexpression of TAp73 repressed CCL2 levels, knockdown of TAp73 using siRNAs 
resulted in an upregulation of CCL2 in human breast cancer cell lines. To show that TAp73-
mediated CCL2 inhibition is NF-κB dependent, we used two small molecule inhibitors 
targeting different stages of the NF-κB pathway. Inhibition of the subunit IKKβ or specifically 
inhibiting p65 resulted in a strong reduction of Ccl2 levels in MEFs deficient for TAp73, 
normalizing Ccl2 to wildtype levels. This demonstrates that the increased expression of Ccl2 
in TAp73 deficient cells is due to NF-κB activity. Additionally, combined deletion of the two 
distal NF-κB binding sites in the Ccl2 promoter, that are known to be important for Ccl2 
expression, resulted in complete inhibition of Ccl2 promoter activity. Adding TAp73β did not 
lead to further reduction, suggesting that these binding sites are essential for Ccl2 promoter 
activity, and that TAp73β suppresses NF-κB-dependent transcriptional activation of the Ccl2 
promoter. 
Since CCL2 is one of the main chemokines involved in macrophage recruitment, we were 
intrigued to investigate the influence that loss of TAp73 in the tumor cells might have on 
macrophages in the tumor microenvironment. In general, not much is known about the 
influence of p73 on macrophages. To date, the only link between p73 and macrophages is a 
study investigating the loss of TAp73 in macrophages in mice. The results indicate that TAp73 
is needed for macrophage activation and innate immunity. A lethal challenge with LPS resulted 
in a more pro-inflammatory activation state of the TAp73-/- macrophages compared to 
wildtype, indicated by higher expression of MHC class II and a decrease in phagocytosis. 
Furthermore, TAp73-/- mice showed higher levels of pro-inflammatory cytokines in the blood, 
such as TNF-α, IL-6 and IL-1β 234.  
In the case of its family member p53 some more data is available describing its influence on 
macrophages in cancer. A recent study by Cooks et al. elucidates the pathway of how mutant 
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p53 is able to reprogram macrophages in the tumor microenvironment to acquire a tumor 
supporting phenotype. There they describe how colon cancer cells with mutant p53 release 
exosomes containing miR-1246. Thereafter, these exosomes are ingested by macrophages 
leading to an alteration in their phenotype, which ultimately has an impact on tumor growth 
235. Furthermore, several studies indicate a role for p53 in the regulation of CCL2. In 
glioblastoma mutant p53 correlated with NF-κB-dependent upregulation of CCL2 236. 
Furthermore, in a murine model for ovarian high-grade serous carcinoma loss of p53 led to 
increased levels of CCL2 and consequently an elevation of infiltrating immunosuppressive 
myeloid cells 237. 
Up to date, the engagement of TAp73 in TAM recruitment and activation state in cancer has 
been entirely unknown. To study the effects of TAp73 loss on TAMs we used two murine in 
vivo models. The first one being a subcutaneous model where we utilized wildtype or TAp73 
deficient transformed MEFs to study tumor growth and the TME. The second model 
represented a more disease relevant model for modelling breast cancer. We utilized the 
MMTV-PyMT model (on a C57Bl/6 background) which develops spontaneous tumors in the 
mammary gland in mice due to the expression of the polyoma virus middle T oncoprotein under 
the mouse mammary tumor virus LTR, which restricts tumor development to the mammary 
epithelium 238. These mice were crossed with TAp73 wildtype or knockout mice and were 
monitored for spontaneous tumor formation. From these tumors cell lines were prepared. The 
cell lines were validated for Ccl2 expression. TAp73 knockout showed increased Ccl2 
expression and secretion compared to wildtype cells. Cells were then injected orthotopically 
into the mammary gland fat pad of wildtype C57Bl/6 mice. This strategy allowed us to 
specifically investigate the effects of loss of TAp73 in tumor cells on the TME, while all other 
cell types were wildtype for TAp73. 
Using these models, we show that loss of TAp73 leads to increased infiltration of TAMs in 
breast cancer. The TAMs were found to present enhanced surface expression of CD206 and 
CD204, indicating a tumor-promoting activation state of the cells. Additionally, we analyzed 
human breast cancer biopsies for TAp73 expression levels and compared those with TAM 
infiltration and activation. Low expression of TAp73 was found to correlate with higher levels 
of CD68 and CD163, markers commonly used for general macrophages or pro-tumoral 
macrophages, respectively. Importantly, a recent study found that high infiltration of CD163 
positive macrophages correlated with poor prognosis in TNBC, furthermore strengthening the 
importance of our findings 239.  
Interestingly, TAMs are known to influence the behavior of mouse breast cancer cells through 
the secretion of TNF-α which induces enhanced NF-κB activity in the cancer cells and 
enhances their invasive potential 240. Increased macrophage infiltration due to an activated NF-
κB pathway in TAp73 deficient tumors and the concurrent increase in TNF-α secretion could 




Taken together, here we identify TAp73 as an important regulator of NF-κB-mediated 
expression of pro-inflammatory cytokines as well as of macrophage recruitment and activation 
in breast cancer (see Figure 9). If TAp73 has this function also in other types of cancer remains 
to be investigated. Considering that TAp73-dependent regulation of the NF-κB pathway was 
not only observed in breast cancer cell lines, but also in transformed MEFs, which were used 
for mechanistic studies, indicates that this mechanism might not be unique to breast cancer. 
Furthermore, coherent with our own findings, loss of TAp73 in macrophages was found to 
increase secretion of pro-inflammatory cytokines 234. Despite macrophages being completely 
different from tumor cells, TAp73 knockout results in the same outcome in both cell types, 
namely an increase of pro-inflammatory factors, pointing to a general role for TAp73 in the 
regulation of NF-κB.  
 
 
Figure 11. The effects of TAp73 on NF-κB regulation and TAM recruitment. 
 
Many different types of cancer are known to have an increased activation of the NF-κB 
pathway as well as high macrophage infiltration, both factors exerting general tumor-
promoting effects 241,242. It might be that TAp73 plays a significant role in regulating tumor 
progression by inhibiting NF-κB and associated tumor-promoting macrophage infiltration, and 
that tumors that manage to overcome this inhibition gain growth advantage through an increase 
in proliferation signals and support by macrophages. TAp73-mediated inhibition of the NF-κB 






3.2 PAPER II 
 
Loss of ΔNp73 leads to an increase in NKG2D ligand expression, while not affecting NK 
cell-mediated tumor cell killing in breast cancer. 
 
NK cells serve as important components of the innate immune system by detecting stressed 
and transformed cells and NK cell infiltration into tumors has been linked to better clinical 
outcome 83,100-102.  
While a few studies highlight a link between p53 activity and NK cell regulation, no data is 
available for other p53 family members. Recently reactivation of wildtype p53 was described 
to improve lysis of tumor cells by NK cells 243. Another study in mice highlighted p53 in the 
regulation of the activating NKG2D ligand, Rae-1ε, identifying p53 binding sites in the gene 
promoter region 244. Furthermore, p53 activation in lung, breast and colon cancer cells led to 
an increase in NKG2D ligands on the cancer cells and more efficient NK cell-mediated killing 
of the tumor cells 245,246. Interestingly, a study showed that in multiple myeloma cells activation 
of the DNA damage response pathway led to an increase in NKG2D ligands in a p53-
independent manner. The ligand upregulation was however dependent on the functionality of 
the E2F-1 transcription factor 247. Intriguingly, E2F-1 is known to activate p73 expression upon 
functional loss of p53 214. Based on this knowledge, we were interested to investigate if p73 
isoforms are able to influence NKG2D ligand expression and thereby play a role in NK cell-
mediated killing of tumor cells.  
In cancer, a balance between tumor-suppressing and oncogenic p73 isoforms regulate the net 
outcome for the cell. In many solid cancers, the expression of ΔNp73, an oncogenic isoform of 
p73, is upregulated and overrules the effects of tumor-suppressing isoforms 201. Therefore, we 
wanted to uncover the effects that the loss of ΔNp73 potentially has on NK cell ligand 
regulation. 
As in Paper I, we utilized the TCGA breast cancer data set to evaluate possible correlations. 
Interestingly, we found a negative correlation between ΔNp73 expression and certain activating 
NK cell ligands, NKG2D ligands, MICB, ULBP1 and ULBP2. On the other hand, a positive 
correlation was detected for the NKG2D ligands MICA and ULBP3. 
To validate the observed correlation, we performed a knock down of ΔNp73 in two human 
breast cancer cell lines (MCF-7 and MDA-MB-231) and studied the expression of NKG2D 
ligands. Knockdown of ΔNp73 in MCF7 cells resulted in increased mRNA and surface 
expression of MICA and MICB as well as ULBP2/5/6. Interestingly, in MDA-MB-231 cells 
mRNA levels of NKG2D ligands were significantly upregulated upon knockdown of ΔNp73. 
However, no detectable difference was observed in surface ligand expression. Cancer cells 
often find a way to avoid NK cell detection and consequent destruction. In the case of the 
MDA-MB-231 cell line, ligand shedding has been described as a common mechanism to evade 
 
34 
immune cell recognition 248. This could explain the detected difference in mRNA versus 
surface expression on these cells.  
To perform ΔNp73 knockdown, two siRNAs were used, recognizing different sequences of the 
mRNA of ΔNp73. These two siRNAs however resulted in similar ΔNp73 knockdown 
efficiency while showing differences in the effect on NKG2D ligand expression. Importantly, 
knockdown of ΔNp73 was detected on mRNA level using Taqman-based real time qPCR. In 
general, to detect the knockdown of a target, evaluation of the protein levels would be preferred, 
since posttranscriptional regulation might influence the total protein levels in the cell. 
Importantly, especially in the case of p73, posttranscriptional modifications and following 
degradation is the main regulatory mechanism of protein availability 249. However, in the case 
of ΔNp73 endogenous protein detection is rather difficult. Actually, one of the biggest 
challenges of the p73 community remains the generation of a functional antibody against the 
ΔNp73 isoforms. Despite great efforts by us and others, so far, no antibody has been 
sufficiently specific. 
Since our results indicate that ΔNp73 negatively regulates NKG2D ligand expression on breast 
cancer cells, we wanted to know what effects ΔNp73 knockdown has on NK cell-mediated 
killing of these cells. Unexpectedly, upon knockdown of ΔNp73 no difference was detected in 
the killing efficiency exerted by the NK cells. Importantly though, NK cells were able to kill 
both MCF7 and MDA-MB-231 cells, which can be concluded from the increasing proportion 
of dead tumor cells upon increasing effector-tumor ratios. However, the presence or absence 
of ΔNp73 in tumor cells did not change the amount of tumor cell killing. 
To figure out what restrains NK cells from elevated killing efficiency even though NKG2D 
ligands are upregulated, we investigated if other NK cell ligands are also deregulated upon 
ΔNp73 knockdown. We were especially interested in the expression of inhibitory NK cell 
ligands. Once more, we used the TCGA breast cancer data set to compare patients with low 
and high ΔNp73 expression. And indeed, we found that low levels of ΔNp73 correlated with 
high expression of the inhibitory NK cell ligands HLA-A, HLA-B and HLA-C. This finding 
was further validated in various cell lines, where we found increased expression of HLA-A, 
HLA-B and HLA-C upon knockdown of ΔNp73. The concurrent upregulation of activating 
and inhibitory NK cell ligands could explain why no difference in NK cell-mediated tumor cell 
killing was detected. In a tumor setting, HLA expression is often downregulated to circumvent 
detection and killing by CD8+ T cells, that use their T cell receptor to interact with HLA class 
I molecules presenting tumor antigens 250. Therefore, an increase of HLA expression upon loss 
of ΔNp73 would suggest improved recognition of the cancer cells by CD8+ T cells. In vivo 
experiments in immune competent mice need to be performed to investigate the net effects of 
simultaneous upregulation of activating and inhibitory NK cell ligands on tumor development.  
In line with our findings, wild type p53 was described to be important in the upregulation of 
MHC class I molecules on the surface of tumor cells, which increased the visibility of the tumor 
cells to cytotoxic T cells 251. Since ΔNp73 is able to inhibit p53 activity, ΔNp73 knockdown 
would release p53 from its inhibition and allow p53 to function, hence leading to an increase 
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in HLA expression on the tumor cells. However, as intriguing as this explanation sounds, our 
data points towards a p53-independent mechanism. When using a colon cancer cell line either 
wildtype or knockout for p53, upon knockdown of ΔNp73 HLA levels showed a trend to be 
upregulated in wildtype as well as in p53 knockout cells. Furthermore, ΔNp73-mediated 
upregulation of MICA and MICB was also found to be independent of p53 status. Interestingly 
though, overall MICA/B levels were lower in p53 deficient cells, indicating a role for p53 in 
NKG2D ligand regulation independent of ΔNp73. 
Since the members of the p53 network can all influence each other, it would be interesting to 
see if other members or isoforms are involved in the regulation of NK cell ligands. Even though 
p53 family members share multiple transcriptional targets, they were all shown to have 
individual functions as well and bind to unique binding partners resulting in differential gene 
expression 156. It is possible that p53 plays a role in NK cell ligand regulation independently of 
ΔNp73. However, it could be interesting to see if TAp73 has effects on NK cell ligand 
regulation in a competitive manner to ΔNp73. It would be possible that high levels of ΔNp73 
inhibit TAp73-mediated expression of NK cell ligands and inhibition of ΔNp73 could release 
TAp73, allowing transcriptional activity.  
 
 
Figure 12. The effects of ΔNp73 levels in tumor cells on NK cell ligand expression and 
NK cell activity. 
In conclusion, we discovered a role for ΔNp73 in the regulation of several NK cell ligands in 
breast cancer (Figure 10). Due to the activating and inhibitory nature of these NK cell ligands 
no difference in NK cell-mediated killing of tumor cells was detected. Furthermore, the exact 




3.3 PAPER III 
 
ΔNp73 enhances HIF-1α protein stability through repression of the ECV complex. 
 
HIF-1α upregulation is a common feature of many human cancers, including breast cancer, and 
correlates with poor survival, see section ‘Hypoxia’ 252-257. 
Various p53 family members have been described to influence the regulation of the HIF-1α 
pathway and angiogenesis. Several reports propose a complex interplay between the 
transcription factors p53 and HIF-1α on protein level. Interestingly, it was discovered that 
hypoxic conditions induce the stabilization of wildtype p53 in a HIF-1α-dependent manner. 
P53 was shown to associate directly with HIF-1α and to be transcriptionally active 258. Later 
p53 was found to mediate proteasomal degradation of HIF-1α via recruiting the E3 ligase 
MDM2 259. Accordingly, p53 was found to suppress the transcription of HIF-1α target genes 
260. Interestingly, HIF-1α was found to compete with p53 for binding to the transcriptional co-
activator p300/CBP thereby inhibiting its transcriptional activity 261. Taken together, loss of 
p53 results in upregulation of HIF-1α target genes, due to a decrease in the competition for 
p300/CBP. On the other hand, severe hypoxia/anoxia induces increased p53 stability and 
thereby promotes HIF-1α degradation, most likely as a mechanism for cells to induce hypoxia-
induced apoptosis. 
Besides p53, ΔNp63, an oncogenic isoform belonging to the p63 proteins, has been identified 
as a regulator of angiogenesis in neuroblastoma and childhood osteosarcoma. ΔNp63 was 
found to induce HIF-1α stabilization and concomitant VEGF secretion via an IL-6/IL-8 – 
STAT3 pathway 262. Conversely, the tumor suppressor TAp63 promotes the expression of 
Sharp-1, which associates with HIF-1α and induces its proteasomal degradation 263. 
Likewise, also p73 proteins are known to regulate hypoxia and HIF-1α target gene expression. 
We have previously established a link between loss of TAp73 and increased angiogenesis and 
HIF-1α target expression 219. At the same time another group reported similar findings. Amelio 
et al. confirmed that TAp73 opposes angiogenesis by interacting with the regulatory subunit of 
HIF-1α. This promotes the recruitment of MDM2 and leads to polyubiquitination and 
concomitant proteasomal degradation of HIF-1α 264. These findings suggest that TAp73 can 
utilize the same mechanism as its family member p53 to promote HIF-1α degradation. Another 
study suggests that hypoxia-induced HIF-1α promotes the stability of the oncogenic p73 
isoform, ΔNp73, by suppressing Siah1. Siah1 is an E3 ligase and was shown to be involved in 
the degradation of p73 proteins. Furthermore, ΔNp73 was shown to promote VEGF secretion 
and tumor angiogenesis 265. At the same time the authors claim that also TAp73 stability is 
regulated by HIF-1α in the same manner. Namely, that under hypoxic conditions HIF-1α 
inhibits Siah1, which suppresses TAp73 degradation and leads to an increase of TAp73 levels 
and that this ultimately promotes tumor progression 266. Even though these results are contrary 
to our own findings and those of others, it could be that the severity of oxygen deprivation in 
the tissue/cells plays a role how TAp73 is functioning, as it has been shown to be the case for 
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p53 267. Furthermore, spatial and temporal differences might be the reason for the opposing 
results. 
While TAp73 deficient tumors displayed increased angiogenesis, we discovered that ΔNp73 
loss was accompanied by a drastic decrease in angiogenesis and reduced tumor growth 219. 
Additionally, another group also reported reduced vessel formation and tumor growth in 
ΔNp73 deficient tumors compared to wildtype tumors 265. Contrary to the disputed role of 
TAp73 in angiogenesis regulation, a promoting role for ΔNp73 in the angiogenic process is 
well established. This being said, so far no one has investigated if ΔNp73 regulates 
angiogenesis by opposing p53/TAp73s regulation of HIF-1α or if it does so in a different 
manner. We were therefore intrigued to uncover the underlying regulatory mechanism how 
ΔNp73 regulates HIF-1α. 
To do so we knocked down ΔNp73 stably using shRNA or transiently with siRNA, in breast 
cancer cell lines MCF-7 and MDA-MB-231. ΔNp73 knockdown led to a reduction of HIF-1α 
protein levels and consequently reduced HIF-1α target gene expression. Interestingly, 
decreased HIF-1α protein levels were observed under hypoxic and normoxic conditions, 
indicating an oxygen-independent regulation by ΔNp73. 
To study the effect of ΔNp73 on HIF-1α regulation in vivo we injected nude mice with 
transformed MEFs, either wildtype or deficient for ΔNp73. HIF-1α protein levels were found 
to be significantly lower in ΔNp73 knockout tumors even after normalization to tumor size. 
HIF-1α levels were investigated in hypoxic and non-hypoxic tumor areas. We found lower 
HIF-1α levels in ΔNp73 knockout tumors in both hypoxic and non-hypoxic areas, compared 
to wildtype tumors.  
Importantly, neither ΔNp73 knockdown nor overexpression affected HIF-1α mRNA 
expression. Inhibiting the 26S-dependent proteasomal degradation machinery we discovered 
that ΔNp73 interferes with the protein stability of HIF-1α. Furthermore, we found increased 
levels of ubiquitin bound to HIF-1α in ΔNp73 knockout cells and upon knockdown of ΔNp73 
in human breast cancer cells.  
To figure out how ΔNp73 regulates proteasomal degradation of HIF-1α we compared HIF-1α 
hydroxylation but could not detect any difference between wildtype or ΔNp73 deficient cells. 
Next, we utilized the human renal cell line RCC4, which normally is VHL deficient but is also 
available as a version that has VHL reintroduced (RCC4+VHL). Knockdown of ΔNp73 in RCC4 
cells did not show any effect on HIF-1α protein levels. However, in RCC4+VHL cells 
knockdown of ΔNp73 led to significantly decreased protein levels of HIF-1α, indicating that 
ΔNp73 interferes with VHL-mediated regulation of HIF-1α. However, no differences in VHL 
mRNA or protein levels were detected upon knockdown of ΔNp73. While VHL seems to be 
crucial for HIF-1α regulation by ΔNp73, the results point out that ΔNp73 does not influence 
HIF-1α via regulating VHL levels. 
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To evaluate which pathways are deregulated by ΔNp73, we used the TCGA breast cancer data 
set and compared samples with low and high ΔNp73 expression. Interestingly, we found 
ubiquitin-mediated proteolysis upregulated in samples expressing low levels of ΔNp73. 
Furthermore, we confirmed our previous findings that ΔNp73 does not affect VHL or HIF-1α 
mRNA expression levels.  
Several of the genes downregulated upon high levels of ΔNp73 were genes involved in the 
ECV complex. We validated the expression of mRNA levels of Elongin B (TCEB2), Elongin 
C (TCEB1), Cullin 2 (CUL2) and Rbx1 (RBX1) and found that all of them were upregulated 
upon ΔNp73 knockdown. Conversely, upon ΔNp73 overexpression the members of the ECV 
complex showed decreased mRNA expression levels. Furthermore, we confirmed elevated 
protein levels of these ECV genes in ΔNp73 deficient cells compared to wildtype. Analysis of 
the promoter regions of the ECV genes identified putative p53/p73 binding sites, which ΔNp73 
would be able to compete for binding to, thereby inhibiting transcription. By performing 
chromatin immunoprecipitation, we were able to validate that ΔNp73 binds to the promoter 
region of RBX1 and TCEB1. Rbx1 is the RING finger protein that together with Cullin 2 is 
necessary for the polyubiquitination of HIF-1α. By silencing the E3 ligase Rbx1, we confirm 
that Rbx1 is essential for HIF-1α degradation. Finally, knocking down both Rbx1 and ΔNp73 
simultaneously did not lead to a decrease in HIF-1α levels, suggesting that the enhanced 
degradation of HIF-1α in absence of ΔNp73 is due to enhanced Rbx1 activity. 
 
 
Figure 13. ΔNp73 induces HIF-1α stability and expression of HIF-1α target genes. 
 
In conclusion, we identify ΔNp73 to be an important regulator of the HIF-1α transcription 
factor. ΔNp73 inhibits expression of members of the ECV complex and thereby promotes HIF-
1α protein stability. ΔNp73 therefore acts through a mechanism unrelated to the one its family 
member TAp73 utilizes to regulate HIF-1α. Overall, these findings once again strengthen 
ΔNp73s role as an oncogenic protein able to influence multiple cellular processes involved in 
tumor progression.   
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3.4 PAPER IV 
 
ΔNp73 regulates the expression of the multidrug-resistance genes ABCB1 and ABCB5 
in breast cancer and melanoma cells - a short report.  
 
Our previous findings that high ΔNp73 expression in breast cancer patient biopsies correlates 
with angiogenesis and hypoxia left us curious to investigate which other pathways are 
differentially regulated in high versus low ΔNp73 expressing samples. Therefore, we utilized 
the TCGA BRCA data set and performed a Kyoto Encyclopedia of Genes and Genomes 
(KEGG) pathway analysis on the genes that were at least 2-fold up- or downregulated in ΔNp73 
high samples compared to samples without detectable ΔNp73 expression. Interestingly, we 
identified the ABC transporter pathway as the most upregulated pathway in ΔNp73 high 
expressing samples. 
ABC transporters are surface glycoproteins that catalyze the export of lipids, metabolic 
products and other small molecules, such as drugs, through intra- and extracellular membranes 
268,269. Cancer cells commonly upregulate ABC transporters as a mechanism to resist killing by 
chemotherapeutic drugs and confer multidrug resistance (see section ‘Multidrug Resistance’) 
154. Importantly, ABC transporter expression correlates with poor prognosis and drug failure in 
many types of cancer 270. 
Our analysis showed that the most significantly upregulated genes in the ΔNp73 high 
expressing samples belonged to the ABC families A (ABCA), B (ABCB), C (ABCC) and G 
(ABCG), with ABCB5 being the highest upregulated gene. 
To validate our findings that ΔNp73 correlates with ABC transporter expression we 
overexpressed ΔNp73α in the breast cancer cell lines MCF-7 and MDA-MB-231. While we 
could not detect any expression of ABCA8, ABCA9 and ABCA10, we were able to detect an 
increase in ABCB1 and ABCB5 mRNA levels. Conversely, by performing transient or stable 
knockdown of ΔNp73 we confirmed a decrease in ABCB1 and ABCB5 expression compared 
to controls. 
ABCB1, commonly referred to as multidrug resistance gene 1 (MDR1) or g-glycoprotein (g-
gp), has been shown to correlate with poor response to chemotherapy in breast cancer 271. In 
melanoma, chemoresistant cells are defined by their increased expression of ABCB1 and 
ABCB5 272. Treatment with chemotherapeutic drugs led to the selection of cells upregulating 
ABCB5 and this data was supported by the analysis of clinical samples of melanoma patients 
that received the chemotherapeutic drug dacarbazine 273. 
The participation of p53 family members in the regulation of ABC transporter is well 
established. Previously, p53 has been shown to play a role in the regulation of ABCB1 
expression. Loss of functional p53 resulted in elevated levels of ABCB1 274.  
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Furthermore, ΔNp73α has been described to cause upregulation of ABCB1, by interfering with 
p53-mediated transcription in gastric cancer 275. So far however, our data for the first time 
present a clear correlation between ΔNp73 and ABC transporters in breast cancer. 
Next, we were interested to investigate if the ΔNp73-mediated upregulation of ABC 
transporters effects cellular responses to drug treatments. Therefore, we treated MCF-7 or 
MDA-MB-231 cells, either control or stable knockdown for ΔNp73, for 30 minutes with 
Doxorubicin and evaluated drug retention directly after or 3 hours after drug treatment. 
Intriguingly, we discovered that cells containing a stable knockdown for ΔNp73 retained more 
of the drug in the cytosol, indicating lower efflux ability. Additionally, cells containing a stable 
knockdown for ΔNp73 showed decreased cell proliferation upon treatment with Doxorubicin 
in a dose-dependent manner. These results suggest that ΔNp73 is actively involved in 
regulating resistance to chemotherapeutic drugs in breast cancer by inducing increased 
expression of ABC transporters (see Figure 14). 
Considering the strong link between ABCB5 and self-renewal, differentiation and drug 
resistance in melanoma 273,276, we were intrigued to investigate if ΔNp73 regulates ABC 
transporter expression also in melanoma. Importantly, the predominantly expressed oncogenic 
p73 isoform in melanoma is p73ΔEx2/3 216. In line with this, in biopsies from melanoma 
patients we could detect the expression of p73ΔEx2/3, however no expression of ΔNp73 was 
detectable. We then correlated p73ΔEx2/3 expression with the expression of ABCB1 and 
ABCB5 in these melanoma samples. ΔNp73 correlated with the expression of both genes, 
however, only the correlation with ABCB5 was statistically significant.  
To confirm these findings, we overexpressed p73ΔEx2/3α or p73ΔEx2/3β in the SK-MEL-28 
human melanoma cell line. As expected, ABCB1 and ABCB5 expression was increased upon 
overexpression of different p73dEx2/3 isoforms. Thus, we confirmed a link between ΔNp73 
and multidrug resistance genes also in melanoma. 
 
 
Figure 14. ΔNp73 promotes multidrug resistance through inducing ABC transporters  
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Considering that p53 proteins have previously been shown to regulate multidrug resistance 
genes and that ΔNp73 has been described to inhibit p53-dependent repression of ABC 
transporters in other types of cancer, the underlying mechanism will most likely be the same in 
breast cancer. It would however be interesting to see if TAp73 holds a similar regulatory 




4 CONCLUSION AND FUTURE PERSPECTIVES 
 
In the current thesis, we identified several novel ways by which p73 proteins control the tumor 
microenvironment (see Figure 15). In Paper I, we established an inhibitory role for TAp73 on 
the NF-κB pathway and we presented that the loss of TAp73 led to an upregulation of NF-κB 
activity and a simultaneous increase in macrophage infiltration into the TME. In Paper II, the 
oncogenic p73 isoform, ΔNp73, was found to influence the expression of various NK cell 
ligands. However, due to the concomitant upregulation of NK cell ligands of activating and 
inhibitory nature, no overall effect on NK cell activity and NK cell-mediated killing of tumor 
cells was detected. In Paper III, ΔNp73 was shown to induce HIF-1α protein stability. We 
revealed that ΔNp73 inhibits the transcription of genes comprising the ECV complex, which 
otherwise polyubiquitinates HIF-1α, leading to its proteasomal degradation. Finally, in Paper 
IV, a correlation between high levels of ΔNp73 and the upregulation of ABCB1 and ABCB5 
was established in breast cancer and melanoma. These two genes belong to the ABC transporter 
family which is known to be involved in multidrug resistance of cancer cells. 
 
 
Figure 15. Novel implications of p73 proteins in regulating the TME 
 
The different members of the p73 family are known to regulate a multitude of processes in 
cancer development and progression. While full-length p73 isoforms, TAp73, were shown to 
play a role in apoptosis, genetic stability, migration and angiogenesis, the N-terminally 
truncated isoforms, ΔNp73, possess oncogenic characteristics promoting cancer stemness, drug 
resistance and EMT, hence fostering invasion and metastasis 218,219,264,277-280. Most studies so 
far have focused on what effects the expression or loss of different p73 isoforms have on the 
cancer cell itself. However, how the expression of different p73 isoforms in cancer cells 
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influences the immune cell compartment in the TME has so far not been studied. In Paper I 
and Paper II, we identified at least two different immune cell types that are affected by p73 
isoforms. In Paper I, we found that loss of TAp73 increased the recruitment of macrophages to 
the TME and these macrophages showed a tumor-promoting activation state. In this study we 
also describe how TAp73 inhibits NF-κB activity. Since the NF-κB pathway is a major 
transcriptional regulator of inflammatory processes it is quite likely that TAp73 loss also affects 
other immune cell types. In our analysis of the TCGA breast cancer data set, we found that 
most genes upregulated in samples expressing low levels of TAp73 belonged to pathways 
related to immune regulations. Furthermore, several of these genes belong to the group of 
cytokines and chemokines, which are responsible for the recruitment of immune cells. Based 
on these facts, TAp73 loss seems to, at least indirectly, influence more than just macrophage 
infiltration. However, this remains to be investigated experimentally.  
Additionally, in Paper II, we discovered that loss of ΔNp73 induces the upregulation of several 
NK cell ligands on cancer cells. Various activating NKG2D ligands as well as inhibitory KIR 
ligands were found to be increased simultaneously upon loss of ΔNp73. Even though we did 
not observe any difference in NK cell-mediated tumor cell killing in an in vitro co-culture set-
up, it cannot be excluded that the scenario in vivo would result in a different outcome. This 
hypothesis stems from the fact that NKG2D, an activating receptor, is not only expressed on 
NK cells but also on various T cell populations. It might therefore be that if we target ΔNp73 
in vivo the accompanied increase of NKG2D ligands might stimulate the activity of T cell 
populations resulting in enhanced tumor killing. Furthermore, the increase of HLA molecules 
upon loss of ΔNp73 could also activate CD8+ T cells, inducing tumor killing. However, without 
proper in vivo experiments these ideas remain purely speculative. Nonetheless, based on the 
results of Paper I and Paper II, it can be concluded that p73 proteins take up an important role 
in regulating parts of the immune cell compartment in cancer, thereby influencing the TME. 
In Paper III, we describe a novel mechanism how ΔNp73 regulates HIF-1α protein stability. 
ΔNp73 was found to suppress the expression of various genes of the regulatory machinery 
involved in HIF-1α degradation. Several members of the p53 family have been previously 
reported to contribute to the regulation of HIF-1α. Importantly, the identified mechanism of 
ΔNp73 is distinct from the one TAp73 and p53 have been described to use to control HIF-1α. 
Our findings highlight the complexity within the p53/p73 family. In the case of HIF-1α, it can 
be concluded that all members of the p53 family contribute to its regulation, indicating a certain 
redundancy, as well as the existence of regulatory mechanisms between the members.  
Paper IV illustrates the correlation between ΔNp73 and the multidrug resistance genes, ABCB1 
and ABCB5, in breast cancer and melanoma. Interestingly, a recent study reported a HIF-1α-
mediated increase of ABCB1 and ABCB5 in ovarian cancer. HIF-1α was shown to bind HRE 
in the ABCB1 and ABCB5 promoters and activate their transcription 281. These results link 
Paper III with Paper IV. High levels of ΔNp73 correlate with increased HIF-1α protein stability 
as well as increased ABCB1 and ABCB5 expression. Therefore, it is possible that the 
underlying mechanism how ΔNp73 initiates ABC transporter expression is that ΔNp73 induces 
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HIF-1α stability, which in turn activates ABC transcription. This is an attractive theory since 
inhibition of HIF-1α was shown to reverse multidrug resistance in colon cancer cells through 
a decrease of ABCB1 282. Furthermore, another study suggests an increased activity of the NF-
κB pathway in a subset of melanoma cells, which expressed high levels of ABCB1 and ABCB5 
272. Strikingly, the NF-κB pathway has been described to induce ABCB1 expression via direct 
binding to a NF-κB response element in the first intron of the ABCB1 gene 283. Considering 
these results, it might be that both loss of TAp73, via an increase in NF-κB activity, and 
increased levels of ΔNp73, via elevated HIF-1α stability, can lead to the upregulation of ABC 
transporters and thereby influence multidrug resistance.  
Our studies provide strong evidence for p73 proteins being important in controlling the TME. 
The fact that p73 proteins can hold opposing functions in cancer and regulate each other’s 
expression levels makes investigating the role of individual isoforms a rather challenging task. 
A complex balance of all p73 isoforms, as well as other members of the p53 family, defines 
cellular outcome. Interestingly, in Paper I, we propose that TAp73 is competing with NF-κB 
for the transcriptional co-activator p300/CBP, thereby inhibiting the transcription of NF-κB 
target genes. All members of the p53 family have been shown to rely on binding to this co-
factor for transcriptional activity 226,227,230,261. Furthermore, p300/CBP has also been shown to 
interact with HIF-1α and as mentioned previously, with NF-κB 284. This competition between 
different transcription factors for transcriptional co-activators adds another layer of complexity 
to an already complex network of interactions and regulation within the p53 family. 
P73 proteins are involved in a multitude of different processes regulating cancer development 
and progression, covering most of the cancer hallmarks defined by Hanahan and Weinberg (see 
Figure 1). Targeting distinct p73 isoforms, and thereby shifting the balance, would affect 
several processes simultaneously, instead of focusing on a single hallmark. Furthermore, since 
p73 isoforms are important during normal development but are expressed at rather low levels 
in healthy tissues in adults, targeting these isoforms might be well tolerated. In cancer, overall 
p73 levels are increased compared to healthy tissue. Promoting TAp73 activity or decreasing 
ΔNp73 levels in cancer cells could therefore have great therapeutic effects. However, so far, 
no promising strategies have been developed that could be used in the clinics.  
The significant involvement of the p53 family network in cancer makes it indispensable to 
understand how the different members interplay. Especially since there is a great deal of 
redundancy between p53 family members, which needs to be understood to be able to 
therapeutically target the network and achieve lasting results. 
In conclusion, the papers comprising this thesis aid in understanding the functions of different 
p73 isoforms in regulating the tumor microenvironment and lay ground for further 






First of all, I want to thank my main supervisor Margareta Wilhelm. Maggan, over the years 
you have been a true inspiration. Your knowledge and dedication when it comes to research is 
unbelievable. Besides to discuss experiments I knew your door was always open and you would 
listen to any problems I had. Even though we didn’t agree on everything, especially color 
panels for figures, we still managed to get everything done. I wish you all the success that you 
deserve with your research and that you keep such a nice group going. Thank you for all your 
support! 
To my co-supervisors, Charlotte Rolny, Andreas Lundqvist and Dhifaf Sirhan: With some 
of you I had more contact, some less. I really valued all your input on the different projects and 
providing me with information and tools on immunology. Charlotte for collaborating and 
helping out a lot with the macrophage project. Andreas for always providing us with antibodies 
when we needed them last minute. And Dhifaf, especially to you, thank you so much for all 
your time and support. You always managed to find time to discuss my projects with me. Good 
luck for all your future steps!  
To all current lab members: Vero, from the first day you joined the lab I felt this positive vibe 
that you bring with you everywhere you go. I really enjoyed our conversations in English, 
Spanish or Swedish, depending on how we felt that day. Also, I already miss going to 
Absolution with you on Thursdays. I always enjoyed taking this break with you! Niek, I am so 
happy you decided to come back to do your PhD in our lab. I really enjoyed our lunches 
together looking at pictures of the newest additions to your parents’ farm. Thank you for always 
helping out with absolutely everything! Good luck with your PhD! Leilei, I really appreciated 
your friendly smile every time we met in the lab and the cute emojis you added in your emails! 
I wish you good luck for your future! :) 
To all previous members of the lab: A big thank you, Habib, for helping me getting started 
with the project. Teaching me a lot in the lab and introducing me to possibilities such as the 
MSA and KIcancer. I really missed your calm spirit in the lab after you left! Marina!! Thanks 
for everything! You really helped me a lot throughout the years. I was always afraid that you 
might leave one day and then you did. We miss you in the lab! Wish you all the best for your 
future! Ana, I’m so glad to see you so happy again! It gave me motivation and showed me that 
there is life after PhD. Also, you are the reason I started playing Squash. I really want to thank 
you for this because it has been almost therapeutic to go and smash a ball against a wall after 
an exhausting day in the lab. Robin, I include you here, because it really feels like you’ve been 
part of our lab. I mean at some point you just showed up in our office sitting next to me every 
day. Good luck for your future! 
I want to thank my mentor at KI, Julian Walfridsson. Thank you for your support and all the 
discussions about future possibilities. I really valued our meetings, to me it almost felt like two 
friends talking about life. 
 
48 
Not to forget, my almost co-supervisor Mikael Karlson. Micke, thank you for taking me into 
your group meetings and journal clubs (even though I have been lousy in attending them during 
the last few months). I really appreciated your input and that you were always eager to help in 
any way you could. Thank you for that! Also a big thanks to all the group members, for nice 
discussions and suggestions for my projects! 
Kiran and Nicolas, thanks for all your input and the help you provided me with my projects. 
It’s been great working with both of you! Also, a big thank you to Jonathan and JJ for their 
collaborations! :) 
Thanks to all collaborators and co-authors! Without you it wouldn’t have been possible! 
I want to thank all the students that helped me out during my time in the lab. I hope you learned 
as much as I did during your stay. Thank you, Janina, Larsen, Aitor and Mark! 
A big thank you to Marie Arsenian Henriksson and all members of her group! For all the 
valuable discussions during our joint meetings. Mariavi, Aida, G, Mustaq, Vittoria, thank 
you for all the fika we had together. Lourdes, a special thanks to you! It has been great being 
your friend. I really appreciate that you were there for me when I needed a friend! <3 
To my MTC friends that finished their PhD before me and left to find happiness in new places: 
It hasn’t been the same here without you guys! Silke, thank you for making me join SATS and 
introducing me to Cardio ENERGY. Thanks for all the ESA sushi lunches and wine or movie 
nights. Thanks for all the fika and the motivation you gave me to finish. You’re so caring and 
thoughtful! I can’t thank you enough to take me into your home when I needed it the most. <3 
Mitch, it’s been great to have a fellow Austrian around. Thank you for bringing Silke back to 
Vienna! I’ll see you there! Vanessiña, my friend! You’ve taught me so much. I love discussing 
the world with you. Thank you for taking me with you to Stockholm Food Movement and other 
insightful evening events, widening my horizon. I can’t wait to meet you in Germany or have 
another trip together to Portugal! <3 And last but not least, Nestito! Best roomie. I’m extremely 
grateful for our friendship, for our endless discussions about life and love, and not to forget, 
for all balcony evenings we had together. I miss you, amigo!  
To all the nice people I met at MTC: Wesam! You were always there for me when I needed 
help or someone to talk to, and also anytime I felt like eating ice-cream. I really appreciate that! 
Hope you come and visit me in Vienna. Benedek, sometimes western medicine needs a touch 
of traditional treatments. Go try acupuncture, I’m quite sure you’d enjoy it. I love it! Thanks 
for all the awesome parties at your place and our hiking and biking trips. I only have the best 
memories! Sharesta, thank you for being such an open and joyful person. Thanks for all our 
fika and climbing sessions. I wish you all the happiness for your future! <3 Mariana, thank 
you for fika, ESA sushi lunches, dinner at your place and the trip to ‘your’ summer house! Too 
bad our plan of travelling South America together didn’t work out. Maybe at some point we 
manage to do it after all. Thank you, Leona, Julian and Chris, I always enjoyed meeting you 
guys in the animal house! Shady, thank you for all the conversations we had on how we 
 
 49 
imagine life, work and our future! With your calm spirit you’ve always helped me look at 
things from a different angle, from where they only looked half as bad. Leonie, I want to thank 
you for being the person you are. So caring and helpful! Good luck with the rest of your PhD. 
Basile, thank you for being there for me when I needed you!!! I won’t forget that! Nicol(a)ina, 
it’s been great spending almost a year with you being around. I miss our weekly pancakes and 
daily ping pong sessions. Twana, I have to tell you I’m always happy to see you. You are such 
a calm, glad person, which just makes it great being around you! Keep up this spirit. Lidia, 
Gergana, Tanzina, Okan, Pavitra, thank you for always helping me out. You’ve all been 
great company in the lab. Graciela, thanks for our short collaboration! I really enjoyed the time 
:). Katrine, thank you for always helping out with antibodies!! Ainhoa, I always enjoyed our 
spontaneous chats at the coffee machine! Good luck with your PhD. Marco, thanks for taking 
over the MSA. Someone had to do it! ;) Sanjana, Pradeepa, Ruining, thanks for engaging in 
the MSA! I had a great time with you guys there! Patrick, we’ve only had a short time together 
in the beginning, but it was a good time and I like to remember it! Thank you :) Carina, thanks 
for always being so welcoming! I wish you and your family all the best. Carol, I like to 
remember the good times we had inside and outside the lab. And I’m really glad we managed 
to stay in contact afterwards! :) 
I also want to thank Gesan, Eva and Åsa, for always helping me out and making my PhD life 
easier. I couldn’t have wished for better support! 
To my friends at KI: Thank you, Mirco, for being such an inspirational person. You are so 
driven by doing good and creating a better place for everyone here at KI. It’s been a joy to be 
part of this and see you in action. Thanks for always caring! Henna, it’s been great having you 
live in the same house. For joint Sunday breakfasts, dinners or movie nights! Gracias, Angeles 
cariña, for all the listening and for your trust in me. I am so thankful for your support and I 
wish you all the best in the world. You deserve it so much! <3 Huthayfa, thanks for being my 
friend for so many years! Thanks for all the parties and also thanks for always helping out when 
I needed it. Aurelie it has been great having you around. I’ll never forget when I met you at 
this random party in Vienna, the world is so small. You’re such a cheerful person and I wish 
you all the best, whatever your path will be! Sissi, thank you for nice brunches/lunches and 
funny talks. You’ve always managed to cheer me up! Felix, we basically just met, but I can 
already say that I will miss you! Vincent and Irene, thank you for being my Austrian and 
Spanish speaking friends. I’m so happy you guys moved to Vienna! It showed me that this step 
is possible :D See you there! Eliane, we met at the very beginning, more than 7 years ago. So 
much has changed over all these years, but I’m so happy to still call you my friend! Susi, thank 
you for being who you are. Your cheerful character mixed with the cocky jokes always made 
me laugh. Good luck for your future steps! Thank you, Tatjana, for our collaborations in the 
beginning and the friendship in the end. I feel like I have learnt a lot from you! Sunjay, thanks 
for many parties and our trip to Greece. I have great memories from it! Thank you, Michalis, 
for being part of my journey here in Sweden from the very start. I hope our paths keep on 
crossing! Good luck with everything!  
 
50 
Fadwina, I don’t know how to put this down in words. We’ve been through a lot together and 
even though we sometimes manage to not see each other for months, I know you are always 
there for me. I’m deeply grateful for your friendship. Love you, my little Fadwina! 
To my friends from the master: Jaime, it’s been great having you around and discussing 
advantages and disadvantages of living in Sweden, as well as sharing books. I hope we keep 
up meeting in Stockholm and Vienna! Good luck finishing your PhD, you’re almost there! Uta, 
I’m happy we spent so much time together lately! I really enjoyed our long walks and talks. I 
wish you all the strength to finish and move to the next step, wherever it will be. Thank you, 
Johanna, for being the first person really speaking Swedish to me. Thanks for taking us to a 
proper Swedish midsummer and all the nice memories from our years together. Mona, finally 
it seems we both made it. It’s been hard times, but we got through it! Thanks for always keeping 
in contact. I hope we manage to meet more often in the future! :) Oscar, thanks for our lunches. 
I wish you all the best with the rest of your PhD! Eleni and Vasilis, I am so glad to have met 
you. You are two of the happiest people I know. Always positive and so helpful! I will never 
forget your great hospitality when I joined your wedding in Greece. Stay as you are, my friends 
<3 
And finally, … what would I have done without you, Nati?! We basically know each other 
since the first day I arrived in Sweden and have been friends ever since. Moving closer and 
closer to each other, in the end we managed to move in together and it has been the best time 
of all these years! Your happy/slightly-to-very-crazy spirit always makes me feel better. Our 
evening dancing sessions can’t be replaced by anything better. And our travel to Norway was 
most likely the most amazing trip one can ever imagine. Even though I will leave, I want you 
to know that there will always be an extra room for you in my place! I love you, Natimaus! <3 
To my friends back home: Tamtam, Gugi, Ingo, Tom, Ines, Patci, Heli, Nora, Georg. You 
can’t imagine how lucky I consider myself to have all of you in my life! Even though I’ve been 
horrible in keeping contact during most of the time I spent in Sweden, every time we met in 
person all of you just made me feel like I’ve never left. Can’t wait to meet you all more often 
soon! <3 
To my family:  No words can express how grateful I am! Mom, Dad, I wouldn’t be here 
without you. Thanks for believing in me and making me feel that I can achieve anything! I love 
you! Jutschi, I couldn’t wish for a better sister. You’re my best friend! Thank you for always 
being there for me. And of course, a massive thank you to all family members and extended 
family members that have been supporting me throughout all my life! I’m so happy to call you 






1 WHO. Cancer, <https://www.who.int/health-topics/cancer> (2018, September). 
2 Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 
646-674, doi:10.1016/j.cell.2011.02.013 (2011). 
3 Pandya, P. H., Murray, M. E., Pollok, K. E. & Renbarger, J. L. The Immune System 
in Cancer Pathogenesis: Potential Therapeutic Approaches. J Immunol Res 2016, 
4273943, doi:10.1155/2016/4273943 (2016). 
4 Hashimoto, T. & Shibasaki, F. Hypoxia-inducible factor as an angiogenic master 
switch. Front Pediatr 3, 33, doi:10.3389/fped.2015.00033 (2015). 
5 Bister, K. Discovery of oncogenes: The advent of molecular cancer research. Proc 
Natl Acad Sci U S A 112, 15259-15260, doi:10.1073/pnas.1521145112 (2015). 
6 Klein, G. Oncogenes and tumor suppressor genes. Acta Oncol 27, 427-437, 
doi:10.3109/02841868809093569 (1988). 
7 Lee, E. Y. & Muller, W. J. Oncogenes and tumor suppressor genes. Cold Spring Harb 
Perspect Biol 2, a003236, doi:10.1101/cshperspect.a003236 (2010). 
8 Croce, C. M. Oncogenes and cancer. N Engl J Med 358, 502-511, 
doi:10.1056/NEJMra072367 (2008). 
9 Wang, L. H., Wu, C. F., Rajasekaran, N. & Shin, Y. K. Loss of Tumor Suppressor 
Gene Function in Human Cancer: An Overview. Cell Physiol Biochem 51, 2647-
2693, doi:10.1159/000495956 (2018). 
10 Kastenhuber, E. R. & Lowe, S. W. Putting p53 in Context. Cell 170, 1062-1078, 
doi:10.1016/j.cell.2017.08.028 (2017). 
11 Leiderman, Y. I., Kiss, S. & Mukai, S. Molecular genetics of RB1--the retinoblastoma 
gene. Semin Ophthalmol 22, 247-254, doi:10.1080/08820530701745165 (2007). 
12 Stambolic, V. et al. Negative regulation of PKB/Akt-dependent cell survival by the 
tumor suppressor PTEN. Cell 95, 29-39, doi:10.1016/s0092-8674(00)81780-8 (1998). 
13 WHO. Breast Cancer, <https://www.who.int/cancer/detection/breastcancer/en/> 
(2018). 
14 Zielonke, N. et al. Evidence for reducing cancer-specific mortality due to screening 
for breast cancer in Europe: A systematic review. Eur J Cancer 127, 191-206, 
doi:10.1016/j.ejca.2019.12.010 (2020). 
15 Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2020. CA Cancer J Clin 70, 
7-30, doi:10.3322/caac.21590 (2020). 
16 Martinez-Perez, C. et al. Current treatment trends and the need for better predictive 
tools in the management of ductal carcinoma in situ of the breast. Cancer Treat Rev 
55, 163-172, doi:10.1016/j.ctrv.2017.03.009 (2017). 
17 Atezolizumab Combo Approved for PD-L1-positive TNBC. Cancer Discov 9, OF2, 
doi:10.1158/2159-8290.CD-NB2019-038 (2019). 
18 Prat, A. et al. Clinical implications of the intrinsic molecular subtypes of breast 
cancer. Breast 24 Suppl 2, S26-35, doi:10.1016/j.breast.2015.07.008 (2015). 
 
52 
19 Fragomeni, S. M., Sciallis, A. & Jeruss, J. S. Molecular Subtypes and Local-Regional 
Control of Breast Cancer. Surg Oncol Clin N Am 27, 95-120, 
doi:10.1016/j.soc.2017.08.005 (2018). 
20 Clarke, R. B. Steroid receptors and proliferation in the human breast. Steroids 68, 
789-794, doi:10.1016/s0039-128x(03)00122-3 (2003). 
21 Lange, C. A. Challenges to defining a role for progesterone in breast cancer. Steroids 
73, 914-921, doi:10.1016/j.steroids.2007.12.023 (2008). 
22 Early Breast Cancer Trialists' Collaborative, G. et al. Relevance of breast cancer 
hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-
level meta-analysis of randomised trials. Lancet 378, 771-784, doi:10.1016/S0140-
6736(11)60993-8 (2011). 
23 Colleoni, M. et al. Chemotherapy is more effective in patients with breast cancer not 
expressing steroid hormone receptors: a study of preoperative treatment. Clin Cancer 
Res 10, 6622-6628, doi:10.1158/1078-0432.CCR-04-0380 (2004). 
24 Wieduwilt, M. J. & Moasser, M. M. The epidermal growth factor receptor family: 
biology driving targeted therapeutics. Cell Mol Life Sci 65, 1566-1584, 
doi:10.1007/s00018-008-7440-8 (2008). 
25 de Azambuja, E. et al. Ki-67 as prognostic marker in early breast cancer: a meta-
analysis of published studies involving 12,155 patients. Br J Cancer 96, 1504-1513, 
doi:10.1038/sj.bjc.6603756 (2007). 
26 Li, Z. H., Hu, P. H., Tu, J. H. & Yu, N. S. Luminal B breast cancer: patterns of 
recurrence and clinical outcome. Oncotarget 7, 65024-65033, 
doi:10.18632/oncotarget.11344 (2016). 
27 Slamon, D. et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J 
Med 365, 1273-1283, doi:10.1056/NEJMoa0910383 (2011). 
28 Rinnerthaler, G., Gampenrieder, S. P. & Greil, R. HER2 Directed Antibody-Drug-
Conjugates beyond T-DM1 in Breast Cancer. Int J Mol Sci 20, 
doi:10.3390/ijms20051115 (2019). 
29 Schroeder, R. L., Stevens, C. L. & Sridhar, J. Small molecule tyrosine kinase 
inhibitors of ErbB2/HER2/Neu in the treatment of aggressive breast cancer. 
Molecules 19, 15196-15212, doi:10.3390/molecules190915196 (2014). 
30 Anders, C. K., Abramson, V., Tan, T. & Dent, R. The Evolution of Triple-Negative 
Breast Cancer: From Biology to Novel Therapeutics. Am Soc Clin Oncol Educ Book 
35, 34-42, doi:10.14694/EDBK_15913510.1200/EDBK_159135 (2016). 
31 Li, J. P. et al. Association of p53 expression with poor prognosis in patients with 
triple-negative breast invasive ductal carcinoma. Medicine (Baltimore) 98, e15449, 
doi:10.1097/MD.0000000000015449 (2019). 
32 Khosravi-Shahi, P., Cabezon-Gutierrez, L. & Custodio-Cabello, S. Metastatic triple 
negative breast cancer: Optimizing treatment options, new and emerging targeted 
therapies. Asia Pac J Clin Oncol 14, 32-39, doi:10.1111/ajco.12748 (2018). 
33 Matthews, N. H., Li, W. Q., Qureshi, A. A., Weinstock, M. A. & Cho, E. in 




34 Zbytek, B. et al. Current concepts of metastasis in melanoma. Expert Rev Dermatol 3, 
569-585, doi:10.1586/17469872.3.5.569 (2008). 
35 Scolyer, R. A., Long, G. V. & Thompson, J. F. Evolving concepts in melanoma 
classification and their relevance to multidisciplinary melanoma patient care. Mol 
Oncol 5, 124-136, doi:10.1016/j.molonc.2011.03.002 (2011). 
36 Rebecca, V. W., Sondak, V. K. & Smalley, K. S. A brief history of melanoma: from 
mummies to mutations. Melanoma Res 22, 114-122, 
doi:10.1097/CMR.0b013e328351fa4d (2012). 
37 Shain, A. H. & Bastian, B. C. From melanocytes to melanomas. Nat Rev Cancer 16, 
345-358, doi:10.1038/nrc.2016.37 (2016). 
38 Ladstein, R. G., Bachmann, I. M., Straume, O. & Akslen, L. A. Ki-67 expression is 
superior to mitotic count and novel proliferation markers PHH3, MCM4 and mitosin 
as a prognostic factor in thick cutaneous melanoma. BMC Cancer 10, 140, 
doi:10.1186/1471-2407-10-140 (2010). 
39 Chapman, P. B. et al. Improved survival with vemurafenib in melanoma with BRAF 
V600E mutation. N Engl J Med 364, 2507-2516, doi:10.1056/NEJMoa1103782 
(2011). 
40 Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic 
melanoma. N Engl J Med 363, 711-723, doi:10.1056/NEJMoa1003466 (2010). 
41 Queirolo, P., Boutros, A., Tanda, E., Spagnolo, F. & Quaglino, P. Immune-
checkpoint inhibitors for the treatment of metastatic melanoma: a model of cancer 
immunotherapy. Semin Cancer Biol 59, 290-297, 
doi:10.1016/j.semcancer.2019.08.001 (2019). 
42 Manzano, J. L. et al. Resistant mechanisms to BRAF inhibitors in melanoma. Ann 
Transl Med 4, 237, doi:10.21037/atm.2016.06.07 (2016). 
43 Baghban, R. et al. Tumor microenvironment complexity and therapeutic implications 
at a glance. Cell Commun Signal 18, 59, doi:10.1186/s12964-020-0530-4 (2020). 
44 Gonzalez, H., Hagerling, C. & Werb, Z. Roles of the immune system in cancer: from 
tumor initiation to metastatic progression. Genes Dev 32, 1267-1284, 
doi:10.1101/gad.314617.118 (2018). 
45 Gouirand, V., Guillaumond, F. & Vasseur, S. Influence of the Tumor 
Microenvironment on Cancer Cells Metabolic Reprogramming. Front Oncol 8, 117, 
doi:10.3389/fonc.2018.00117 (2018). 
46 Epelman, S., Lavine, K. J. & Randolph, G. J. Origin and functions of tissue 
macrophages. Immunity 41, 21-35, doi:10.1016/j.immuni.2014.06.013 (2014). 
47 Hoeffel, G. & Ginhoux, F. Fetal monocytes and the origins of tissue-resident 
macrophages. Cell Immunol 330, 5-15, doi:10.1016/j.cellimm.2018.01.001 (2018). 
48 Kaufmann, S. H. E. & Dorhoi, A. Molecular Determinants in Phagocyte-Bacteria 
Interactions. Immunity 44, 476-491, doi:10.1016/j.immuni.2016.02.014 (2016). 
49 Gaudino, S. J. & Kumar, P. Cross-Talk Between Antigen Presenting Cells and T 
Cells Impacts Intestinal Homeostasis, Bacterial Infections, and Tumorigenesis. Front 
Immunol 10, 360, doi:10.3389/fimmu.2019.00360 (2019). 
 
54 
50 Leopold Wager, C. M. & Wormley, F. L., Jr. Classical versus alternative macrophage 
activation: the Ying and the Yang in host defense against pulmonary fungal 
infections. Mucosal Immunol 7, 1023-1035, doi:10.1038/mi.2014.65 (2014). 
51 Bertani, F. R. et al. Classification of M1/M2-polarized human macrophages by label-
free hyperspectral reflectance confocal microscopy and multivariate analysis. Sci Rep 
7, 8965, doi:10.1038/s41598-017-08121-8 (2017). 
52 He, Y. et al. Clinical and transcriptional signatures of human CD204 reveal an 
applicable marker for the protumor phenotype of tumor-associated macrophages in 
breast cancer. Aging (Albany NY) 11, 10883-10901, doi:10.18632/aging.102490 
(2019). 
53 Mosser, D. M. & Edwards, J. P. Exploring the full spectrum of macrophage 
activation. Nat Rev Immunol 8, 958-969, doi:10.1038/nri2448 (2008). 
54 Murray, P. J. et al. Macrophage activation and polarization: nomenclature and 
experimental guidelines. Immunity 41, 14-20, doi:10.1016/j.immuni.2014.06.008 
(2014). 
55 Solinas, G., Germano, G., Mantovani, A. & Allavena, P. Tumor-associated 
macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc 
Biol 86, 1065-1073, doi:10.1189/jlb.0609385 (2009). 
56 Zhao, X. et al. Prognostic significance of tumor-associated macrophages in breast 
cancer: a meta-analysis of the literature. Oncotarget 8, 30576-30586, 
doi:10.18632/oncotarget.15736 (2017). 
57 Mei, J. et al. Prognostic impact of tumor-associated macrophage infiltration in non-
small cell lung cancer: A systemic review and meta-analysis. Oncotarget 7, 34217-
34228, doi:10.18632/oncotarget.9079 (2016). 
58 Lewis, C. E. & Pollard, J. W. Distinct role of macrophages in different tumor 
microenvironments. Cancer Res 66, 605-612, doi:10.1158/0008-5472.CAN-05-4005 
(2006). 
59 Allavena, P., Sica, A., Garlanda, C. & Mantovani, A. The Yin-Yang of tumor-
associated macrophages in neoplastic progression and immune surveillance. Immunol 
Rev 222, 155-161, doi:10.1111/j.1600-065X.2008.00607.x (2008). 
60 Quail, D. F. & Joyce, J. A. Microenvironmental regulation of tumor progression and 
metastasis. Nat Med 19, 1423-1437, doi:10.1038/nm.3394 (2013). 
61 Movahedi, K. et al. Different tumor microenvironments contain functionally distinct 
subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res 70, 5728-
5739, doi:10.1158/0008-5472.CAN-09-4672 (2010). 
62 Cassetta, L. & Pollard, J. W. Targeting macrophages: therapeutic approaches in 
cancer. Nat Rev Drug Discov 17, 887-904, doi:10.1038/nrd.2018.169 (2018). 
63 Rogers, T. L. & Holen, I. Tumour macrophages as potential targets of 
bisphosphonates. J Transl Med 9, 177, doi:10.1186/1479-5876-9-177 (2011). 
64 Germano, G. et al. Role of macrophage targeting in the antitumor activity of 
trabectedin. Cancer Cell 23, 249-262, doi:10.1016/j.ccr.2013.01.008 (2013). 
65 Li, M., Knight, D. A., L, A. S., Smyth, M. J. & Stewart, T. J. A role for CCL2 in both 




66 Ries, C. H. et al. Targeting tumor-associated macrophages with anti-CSF-1R 
antibody reveals a strategy for cancer therapy. Cancer Cell 25, 846-859, 
doi:10.1016/j.ccr.2014.05.016 (2014). 
67 Bonapace, L. et al. Cessation of CCL2 inhibition accelerates breast cancer metastasis 
by promoting angiogenesis. Nature 515, 130-133, doi:10.1038/nature13862 (2014). 
68 Weiskopf, K. et al. CD47-blocking immunotherapies stimulate macrophage-mediated 
destruction of small-cell lung cancer. J Clin Invest 126, 2610-2620, 
doi:10.1172/JCI81603 (2016). 
69 Adams, S. et al. Topical TLR7 agonist imiquimod can induce immune-mediated 
rejection of skin metastases in patients with breast cancer. Clin Cancer Res 18, 6748-
6757, doi:10.1158/1078-0432.CCR-12-1149 (2012). 
70 Khalil, M. & Vonderheide, R. H. Anti-CD40 agonist antibodies: preclinical and 
clinical experience. Update Cancer Ther 2, 61-65, doi:10.1016/j.uct.2007.06.001 
(2007). 
71 Georgoudaki, A. M. et al. Reprogramming Tumor-Associated Macrophages by 
Antibody Targeting Inhibits Cancer Progression and Metastasis. Cell Rep 15, 2000-
2011, doi:10.1016/j.celrep.2016.04.084 (2016). 
72 Kaneda, M. M. et al. PI3Kgamma is a molecular switch that controls immune 
suppression. Nature 539, 437-442, doi:10.1038/nature19834 (2016). 
73 Gordon, S. R. et al. PD-1 expression by tumour-associated macrophages inhibits 
phagocytosis and tumour immunity. Nature 545, 495-499, doi:10.1038/nature22396 
(2017). 
74 Darvin, P., Toor, S. M., Sasidharan Nair, V. & Elkord, E. Immune checkpoint 
inhibitors: recent progress and potential biomarkers. Exp Mol Med 50, 1-11, 
doi:10.1038/s12276-018-0191-1 (2018). 
75 Zhang, Y. et al. High-infiltration of tumor-associated macrophages predicts 
unfavorable clinical outcome for node-negative breast cancer. PLoS One 8, e76147, 
doi:10.1371/journal.pone.0076147 (2013). 
76 Ramos, R. N. et al. CD163(+) tumor-associated macrophage accumulation in breast 
cancer patients reflects both local differentiation signals and systemic skewing of 
monocytes. Clin Transl Immunology 9, e1108, doi:10.1002/cti2.1108 (2020). 
77 Campbell, M. J. et al. Proliferating macrophages associated with high grade, hormone 
receptor negative breast cancer and poor clinical outcome. Breast Cancer Res Treat 
128, 703-711, doi:10.1007/s10549-010-1154-y (2011). 
78 Stovgaard, E. S., Nielsen, D., Hogdall, E. & Balslev, E. Triple negative breast cancer 
- prognostic role of immune-related factors: a systematic review. Acta Oncol 57, 74-
82, doi:10.1080/0284186X.2017.1400180 (2018). 
79 Larionova, I. et al. Interaction of tumor-associated macrophages and cancer 
chemotherapy. Oncoimmunology 8, 1596004, doi:10.1080/2162402X.2019.1596004 
(2019). 
80 Laoui, D. et al. Tumor-associated macrophages in breast cancer: distinct subsets, 
distinct functions. Int J Dev Biol 55, 861-867, doi:10.1387/ijdb.113371dl (2011). 
81 Ma, R. Y. et al. Monocyte-derived macrophages promote breast cancer bone 
metastasis outgrowth. J Exp Med 217, doi:10.1084/jem.20191820 (2020). 
 
56 
82 Bieniasz-Krzywiec, P. et al. Podoplanin-Expressing Macrophages Promote 
Lymphangiogenesis and Lymphoinvasion in Breast Cancer. Cell Metab 30, 917-936 
e910, doi:10.1016/j.cmet.2019.07.015 (2019). 
83 Mandal, A. & Viswanathan, C. Natural killer cells: In health and disease. Hematol 
Oncol Stem Cell Ther 8, 47-55, doi:10.1016/j.hemonc.2014.11.006 (2015). 
84 Kiessling, R., Klein, E., Pross, H. & Wigzell, H. "Natural" killer cells in the mouse. 
II. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics 
of the killer cell. Eur J Immunol 5, 117-121, doi:10.1002/eji.1830050209 (1975). 
85 Ljunggren, H. G. & Karre, K. Host-Resistance Directed Selectively against H-2-
Deficient Lymphoma Variants - Analysis of the Mechanism. J Exp Med 162, 1745-
1759, doi:DOI 10.1084/jem.162.6.1745 (1985). 
86 Hilton, H. G. & Parham, P. Missing or altered self: human NK cell receptors that 
recognize HLA-C. Immunogenetics 69, 567-579, doi:10.1007/s00251-017-1001-y 
(2017). 
87 Kumar, S. Natural killer cell cytotoxicity and its regulation by inhibitory receptors. 
Immunology 154, 383-393, doi:10.1111/imm.12921 (2018). 
88 Fauriat, C., Long, E. O., Ljunggren, H. G. & Bryceson, Y. T. Regulation of human 
NK-cell cytokine and chemokine production by target cell recognition. Blood 115, 
2167-2176, doi:10.1182/blood-2009-08-238469 (2010). 
89 Pende, D. et al. Killer Ig-Like Receptors (KIRs): Their Role in NK Cell Modulation 
and Developments Leading to Their Clinical Exploitation. Front Immunol 10, 1179, 
doi:10.3389/fimmu.2019.01179 (2019). 
90 Kaiser, B. K., Pizarro, J. C., Kerns, J. & Strong, R. K. Structural basis for 
NKG2A/CD94 recognition of HLA-E. Proc Natl Acad Sci U S A 105, 6696-6701, 
doi:10.1073/pnas.0802736105 (2008). 
91 Jamieson, A. M. et al. The role of the NKG2D immunoreceptor in immune cell 
activation and natural killing. Immunity 17, 19-29, doi:10.1016/s1074-
7613(02)00333-3 (2002). 
92 Lopez-Botet, M. et al. Paired inhibitory and triggering NK cell receptors for HLA 
class I molecules. Hum Immunol 61, 7-17, doi:10.1016/s0198-8859(99)00161-5 
(2000). 
93 Romee, R. et al. NK cell CD16 surface expression and function is regulated by a 
disintegrin and metalloprotease-17 (ADAM17). Blood 121, 3599-3608, 
doi:10.1182/blood-2012-04-425397 (2013). 
94 Sivori, S. et al. Human NK cells: surface receptors, inhibitory checkpoints, and 
translational applications. Cell Mol Immunol 16, 430-441, doi:10.1038/s41423-019-
0206-4 (2019). 
95 Cooper, M. A., Fehniger, T. A. & Caligiuri, M. A. The biology of human natural 
killer-cell subsets. Trends Immunol 22, 633-640, doi:10.1016/s1471-4906(01)02060-9 
(2001). 
96 Gasteiger, G. et al. IL-2-dependent tuning of NK cell sensitivity for target cells is 




97 Yang, Y. et al. Thioredoxin activity confers resistance against oxidative stress in 
tumor-infiltrating NK cells. J Clin Invest, doi:10.1172/JCI137585 (2020). 
98 Carson, W. E. et al. Interleukin (IL) 15 is a novel cytokine that activates human 
natural killer cells via components of the IL-2 receptor. J Exp Med 180, 1395-1403, 
doi:10.1084/jem.180.4.1395 (1994). 
99 Carrega, P. et al. Natural killer cells infiltrating human nonsmall-cell lung cancer are 
enriched in CD56 bright CD16(-) cells and display an impaired capability to kill 
tumor cells. Cancer 112, 863-875, doi:10.1002/cncr.23239 (2008). 
100 Muntasell, A. et al. NK Cell Infiltrates and HLA Class I Expression in Primary 
HER2(+) Breast Cancer Predict and Uncouple Pathological Response and Disease-
free Survival. Clin Cancer Res 25, 1535-1545, doi:10.1158/1078-0432.CCR-18-2365 
(2019). 
101 Villegas, F. R. et al. Prognostic significance of tumor infiltrating natural killer cells 
subset CD57 in patients with squamous cell lung cancer. Lung Cancer 35, 23-28, 
doi:10.1016/s0169-5002(01)00292-6 (2002). 
102 Ishigami, S. et al. Prognostic value of intratumoral natural killer cells in gastric 
carcinoma. Cancer 88, 577-583 (2000). 
103 Lamas, B. et al. Altered functions of natural killer cells in response to L-Arginine 
availability. Cell Immunol 280, 182-190, doi:10.1016/j.cellimm.2012.11.018 (2012). 
104 Huang, B. et al. Gr-1+CD115+ immature myeloid suppressor cells mediate the 
development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing 
host. Cancer Res 66, 1123-1131, doi:10.1158/0008-5472.CAN-05-1299 (2006). 
105 Ghiringhelli, F. et al. CD4+CD25+ regulatory T cells inhibit natural killer cell 
functions in a transforming growth factor-beta-dependent manner. J Exp Med 202, 
1075-1085, doi:10.1084/jem.20051511 (2005). 
106 Schuster, I. S., Coudert, J. D., Andoniou, C. E. & Degli-Esposti, M. A. "Natural 
Regulators": NK Cells as Modulators of T Cell Immunity. Front Immunol 7, 235, 
doi:10.3389/fimmu.2016.00235 (2016). 
107 Tosello-Trampont, A., Surette, F. A., Ewald, S. E. & Hahn, Y. S. Immunoregulatory 
Role of NK Cells in Tissue Inflammation and Regeneration. Front Immunol 8, 301, 
doi:10.3389/fimmu.2017.00301 (2017). 
108 Guerra, N. et al. NKG2D-deficient mice are defective in tumor surveillance in models 
of spontaneous malignancy. Immunity 28, 571-580, 
doi:10.1016/j.immuni.2008.02.016 (2008). 
109 Groh, V., Wu, J., Yee, C. & Spies, T. Tumour-derived soluble MIC ligands impair 
expression of NKG2D and T-cell activation. Nature 419, 734-738, 
doi:10.1038/nature01112 (2002). 
110 Garrido, F., Aptsiauri, N., Doorduijn, E. M., Garcia Lora, A. M. & van Hall, T. The 
urgent need to recover MHC class I in cancers for effective immunotherapy. Curr 
Opin Immunol 39, 44-51, doi:10.1016/j.coi.2015.12.007 (2016). 
111 Ardolino, M. et al. Cytokine therapy reverses NK cell anergy in MHC-deficient 
tumors. J Clin Invest 124, 4781-4794, doi:10.1172/JCI74337 (2014). 
 
58 
112 Torelli, G. F. et al. Recognition of adult and pediatric acute lymphoblastic leukemia 
blasts by natural killer cells. Haematologica 99, 1248-1254, 
doi:10.3324/haematol.2013.101931 (2014). 
113 Mehta, R. S., Randolph, B., Daher, M. & Rezvani, K. NK cell therapy for 
hematologic malignancies. Int J Hematol 107, 262-270, doi:10.1007/s12185-018-
2407-5 (2018). 
114 de Kruijf, E. M. et al. NKG2D ligand tumor expression and association with clinical 
outcome in early breast cancer patients: an observational study. BMC Cancer 12, 24, 
doi:10.1186/1471-2407-12-24 (2012). 
115 Dewan, M. Z. et al. Natural killer activity of peripheral-blood mononuclear cells in 
breast cancer patients. Biomed Pharmacother 63, 703-706, 
doi:10.1016/j.biopha.2009.02.003 (2009). 
116 Gennari, R. et al. Pilot study of the mechanism of action of preoperative trastuzumab 
in patients with primary operable breast tumors overexpressing HER2. Clin Cancer 
Res 10, 5650-5655, doi:10.1158/1078-0432.CCR-04-0225 (2004). 
117 Roberti, M. P. et al. IL-15 and IL-2 increase Cetuximab-mediated cellular 
cytotoxicity against triple negative breast cancer cell lines expressing EGFR. Breast 
Cancer Res Treat 130, 465-475, doi:10.1007/s10549-011-1360-2 (2011). 
118 Heidland, A., Klassen, A., Rutkowski, P. & Bahner, U. The contribution of Rudolf 
Virchow to the concept of inflammation: what is still of importance? J Nephrol 19 
Suppl 10, S102-109 (2006). 
119 Singh, N. et al. Inflammation and cancer. Ann Afr Med 18, 121-126, 
doi:10.4103/aam.aam_56_18 (2019). 
120 Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J. & Schreiber, R. D. Cancer 
immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3, 991-998, 
doi:10.1038/ni1102-991 (2002). 
121 Smyth, E. C., Nilsson, M., Grabsch, H. I., van Grieken, N. C. & Lordick, F. Gastric 
cancer. Lancet 396, 635-648, doi:10.1016/S0140-6736(20)31288-5 (2020). 
122 Pazgan-Simon, M. et al. Hepatitis B virus treatment in hepatocellular carcinoma 
patients prolongs survival and reduces the risk of cancer recurrence. Clin Exp Hepatol 
4, 210-216, doi:10.5114/ceh.2018.78127 (2018). 
123 Jee, B., Yadav, R., Pankaj, S. & Shahi, S. K. Immunology of HPV-mediated cervical 
cancer: current understanding. Int Rev Immunol, 1-20, 
doi:10.1080/08830185.2020.1811859 (2020). 
124 Culig, Z. Cytokine disbalance in common human cancers. Biochim Biophys Acta 
1813, 308-314, doi:10.1016/j.bbamcr.2010.12.010 (2011). 
125 Esfahani, K. et al. A review of cancer immunotherapy: from the past, to the present, 
to the future. Curr Oncol 27, S87-S97, doi:10.3747/co.27.5223 (2020). 
126 Zhang, Q., Lenardo, M. J. & Baltimore, D. 30 Years of NF-kappaB: A Blossoming of 
Relevance to Human Pathobiology. Cell 168, 37-57, doi:10.1016/j.cell.2016.12.012 
(2017). 
127 Sun, S. C. The non-canonical NF-kappaB pathway in immunity and inflammation. 
Nat Rev Immunol 17, 545-558, doi:10.1038/nri.2017.52 (2017). 
 
 59 
128 Taniguchi, K. & Karin, M. NF-kappaB, inflammation, immunity and cancer: coming 
of age. Nat Rev Immunol 18, 309-324, doi:10.1038/nri.2017.142 (2018). 
129 Ligtenberg, M. A., Rojas-Colonelli, N., Kiessling, R. & Lladser, A. NF-kappaB 
activation during intradermal DNA vaccination is essential for eliciting tumor 
protective antigen-specific CTL responses. Hum Vaccin Immunother 9, 2189-2195, 
doi:10.4161/hv.25699 (2013). 
130 Mieczkowski, J. et al. Down-regulation of IKKbeta expression in glioma-infiltrating 
microglia/macrophages is associated with defective inflammatory/immune gene 
responses in glioblastoma. Oncotarget 6, 33077-33090, doi:10.18632/oncotarget.5310 
(2015). 
131 Xia, Y., Shen, S. & Verma, I. M. NF-kappaB, an active player in human cancers. 
Cancer Immunol Res 2, 823-830, doi:10.1158/2326-6066.CIR-14-0112 (2014). 
132 McKeown, S. R. Defining normoxia, physoxia and hypoxia in tumours-implications 
for treatment response. Br J Radiol 87, 20130676, doi:10.1259/bjr.20130676 (2014). 
133 Eltzschig, H. K. & Carmeliet, P. Hypoxia and inflammation. N Engl J Med 364, 656-
665, doi:10.1056/NEJMra0910283 (2011). 
134 Robinson, C. M. & Ohh, M. The multifaceted von Hippel-Lindau tumour suppressor 
protein. FEBS Lett 588, 2704-2711, doi:10.1016/j.febslet.2014.02.026 (2014). 
135 Sufan, R. I. & Ohh, M. Role of the NEDD8 modification of Cul2 in the sequential 
activation of ECV complex. Neoplasia 8, 956-963, doi:10.1593/neo.06520 (2006). 
136 Muz, B., de la Puente, P., Azab, F. & Azab, A. K. The role of hypoxia in cancer 
progression, angiogenesis, metastasis, and resistance to therapy. Hypoxia (Auckl) 3, 
83-92, doi:10.2147/HP.S93413 (2015). 
137 Henze, A. T. & Mazzone, M. The impact of hypoxia on tumor-associated 
macrophages. J Clin Invest 126, 3672-3679, doi:10.1172/JCI84427 (2016). 
138 Deng, B. et al. Intratumor hypoxia promotes immune tolerance by inducing 
regulatory T cells via TGF-beta1 in gastric cancer. PLoS One 8, e63777, 
doi:10.1371/journal.pone.0063777 (2013). 
139 Cummins, E. P. et al. Prolyl hydroxylase-1 negatively regulates IkappaB kinase-beta, 
giving insight into hypoxia-induced NFkappaB activity. Proc Natl Acad Sci U S A 
103, 18154-18159, doi:10.1073/pnas.0602235103 (2006). 
140 Bonello, S. et al. Reactive oxygen species activate the HIF-1alpha promoter via a 
functional NFkappaB site. Arterioscler Thromb Vasc Biol 27, 755-761, 
doi:10.1161/01.ATV.0000258979.92828.bc (2007). 
141 Rius, J. et al. NF-kappaB links innate immunity to the hypoxic response through 
transcriptional regulation of HIF-1alpha. Nature 453, 807-811, 
doi:10.1038/nature06905 (2008). 
142 Vaupel, P. & Mayer, A. Hypoxia in cancer: significance and impact on clinical 
outcome. Cancer Metastasis Rev 26, 225-239, doi:10.1007/s10555-007-9055-1 
(2007). 
143 Hanahan, D. & Folkman, J. Patterns and emerging mechanisms of the angiogenic 




144 Adams, R. H. & Alitalo, K. Molecular regulation of angiogenesis and 
lymphangiogenesis. Nat Rev Mol Cell Biol 8, 464-478, doi:10.1038/nrm2183 (2007). 
145 Schaaf, M. B., Garg, A. D. & Agostinis, P. Defining the role of the tumor vasculature 
in antitumor immunity and immunotherapy. Cell Death Dis 9, 115, 
doi:10.1038/s41419-017-0061-0 (2018). 
146 Deryugina, E. I. & Quigley, J. P. Tumor angiogenesis: MMP-mediated induction of 
intravasation- and metastasis-sustaining neovasculature. Matrix Biol 44-46, 94-112, 
doi:10.1016/j.matbio.2015.04.004 (2015). 
147 Bacic, I. et al. Tumor angiogenesis as an important prognostic factor in advanced 
non-small cell lung cancer (Stage IIIA). Oncol Lett 15, 2335-2339, 
doi:10.3892/ol.2017.7576 (2018). 
148 Tse, G. M. et al. Strong immunohistochemical expression of vascular endothelial 
growth factor predicts overall survival in head and neck squamous cell carcinoma. 
Ann Surg Oncol 14, 3558-3565, doi:10.1245/s10434-007-9632-0 (2007). 
149 Nakamura, Y. et al. Lymph vessel density correlates with nodal status, VEGF-C 
expression, and prognosis in breast cancer. Breast Cancer Res Treat 91, 125-132, 
doi:10.1007/s10549-004-5783-x (2005). 
150 Haibe, Y. et al. Resistance Mechanisms to Anti-angiogenic Therapies in Cancer. 
Front Oncol 10, 221, doi:10.3389/fonc.2020.00221 (2020). 
151 McGranahan, N. & Swanton, C. Clonal Heterogeneity and Tumor Evolution: Past, 
Present, and the Future. Cell 168, 613-628, doi:10.1016/j.cell.2017.01.018 (2017). 
152 Vasan, N., Baselga, J. & Hyman, D. M. A view on drug resistance in cancer. Nature 
575, 299-309, doi:10.1038/s41586-019-1730-1 (2019). 
153 Zaretsky, J. M. et al. Mutations Associated with Acquired Resistance to PD-1 
Blockade in Melanoma. N Engl J Med 375, 819-829, doi:10.1056/NEJMoa1604958 
(2016). 
154 Fletcher, J. I., Haber, M., Henderson, M. J. & Norris, M. D. ABC transporters in 
cancer: more than just drug efflux pumps. Nat Rev Cancer 10, 147-156, 
doi:10.1038/nrc2789 (2010). 
155 Kuo, M. T. Roles of multidrug resistance genes in breast cancer chemoresistance. Adv 
Exp Med Biol 608, 23-30, doi:10.1007/978-0-387-74039-3_2 (2007). 
156 Harms, K., Nozell, S. & Chen, X. The common and distinct target genes of the p53 
family transcription factors. Cell Mol Life Sci 61, 822-842, doi:10.1007/s00018-003-
3304-4 (2004). 
157 Collavin, L., Lunardi, A. & Del Sal, G. p53-family proteins and their regulators: hubs 
and spokes in tumor suppression. Cell Death Differ 17, 901-911, 
doi:10.1038/cdd.2010.35 (2010). 
158 Dotsch, V., Bernassola, F., Coutandin, D., Candi, E. & Melino, G. p63 and p73, the 
ancestors of p53. Cold Spring Harb Perspect Biol 2, a004887, 
doi:10.1101/cshperspect.a004887 (2010). 
159 Yang, A., Kaghad, M., Caput, D. & McKeon, F. On the shoulders of giants: p63, p73 




160 Saadatzadeh, M. R. et al. The Role of MDM2 in Promoting Genome Stability versus 
Instability. Int J Mol Sci 18, doi:10.3390/ijms18102216 (2017). 
161 Wallace, M., Worrall, E., Pettersson, S., Hupp, T. R. & Ball, K. L. Dual-site 
regulation of MDM2 E3-ubiquitin ligase activity. Mol Cell 23, 251-263, 
doi:10.1016/j.molcel.2006.05.029 (2006). 
162 Wu, H. & Leng, R. P. MDM2 mediates p73 ubiquitination: a new molecular 
mechanism for suppression of p73 function. Oncotarget 6, 21479-21492, 
doi:10.18632/oncotarget.4086 (2015). 
163 Carr, M. I. & Jones, S. N. Regulation of the Mdm2-p53 signaling axis in the DNA 
damage response and tumorigenesis. Transl Cancer Res 5, 707-724, 
doi:10.21037/tcr.2016.11.75 (2016). 
164 Li, J. & Kurokawa, M. Regulation of MDM2 Stability After DNA Damage. J Cell 
Physiol 230, 2318-2327, doi:10.1002/jcp.24994 (2015). 
165 Wu, X., Bayle, J. H., Olson, D. & Levine, A. J. The p53-mdm-2 autoregulatory 
feedback loop. Genes Dev 7, 1126-1132, doi:10.1101/gad.7.7a.1126 (1993). 
166 Rossi, M. et al. The ubiquitin-protein ligase Itch regulates p73 stability. EMBO J 24, 
836-848, doi:10.1038/sj.emboj.7600444 (2005). 
167 Rossi, M. et al. Itch/AIP4 associates with and promotes p63 protein degradation. Cell 
Cycle 5, 1816-1822, doi:10.4161/cc.5.16.2861 (2006). 
168 Levy, D., Adamovich, Y., Reuven, N. & Shaul, Y. The Yes-associated protein 1 
stabilizes p73 by preventing Itch-mediated ubiquitination of p73. Cell Death Differ 
14, 743-751, doi:10.1038/sj.cdd.4402063 (2007). 
169 Van Nostrand, J. L., Bowen, M. E., Vogel, H., Barna, M. & Attardi, L. D. The p53 
family members have distinct roles during mammalian embryonic development. Cell 
Death Differ 24, 575-579, doi:10.1038/cdd.2016.128 (2017). 
170 Wei, J., Zaika, E. & Zaika, A. p53 Family: Role of Protein Isoforms in Human 
Cancer. J Nucleic Acids 2012, 687359, doi:10.1155/2012/687359 (2012). 
171 Levine, A. J. & Oren, M. The first 30 years of p53: growing ever more complex. Nat 
Rev Cancer 9, 749-758, doi:10.1038/nrc2723 (2009). 
172 Olivier, M., Hollstein, M. & Hainaut, P. TP53 mutations in human cancers: origins, 
consequences, and clinical use. Cold Spring Harb Perspect Biol 2, a001008, 
doi:10.1101/cshperspect.a001008 (2010). 
173 Oren, M. & Rotter, V. Mutant p53 gain-of-function in cancer. Cold Spring Harb 
Perspect Biol 2, a001107, doi:10.1101/cshperspect.a001107 (2010). 
174 Soussi, T. The history of p53. A perfect example of the drawbacks of scientific 
paradigms. EMBO Rep 11, 822-826, doi:10.1038/embor.2010.159 (2010). 
175 Lane, D. P. Cancer. p53, guardian of the genome. Nature 358, 15-16, 
doi:10.1038/358015a0 (1992). 
176 Zhu, J. Y., Abate, M., Rice, P. W. & Cole, C. N. The ability of simian virus 40 large 
T antigen to immortalize primary mouse embryo fibroblasts cosegregates with its 




177 Scheffner, M., Huibregtse, J. M., Vierstra, R. D. & Howley, P. M. The HPV-16 E6 
and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of 
p53. Cell 75, 495-505, doi:10.1016/0092-8674(93)90384-3 (1993). 
178 Fischer, M., Uxa, S., Stanko, C., Magin, T. M. & Engeland, K. Human papilloma 
virus E7 oncoprotein abrogates the p53-p21-DREAM pathway. Sci Rep 7, 2603, 
doi:10.1038/s41598-017-02831-9 (2017). 
179 Lomax, M. & Fried, M. Polyoma virus disrupts ARF signaling to p53. Oncogene 20, 
4951-4960, doi:10.1038/sj.onc.1204717 (2001). 
180 Donehower, L. A. et al. Mice deficient for p53 are developmentally normal but 
susceptible to spontaneous tumours. Nature 356, 215-221, doi:10.1038/356215a0 
(1992). 
181 Sah, V. P. et al. A subset of p53-deficient embryos exhibit exencephaly. Nat Genet 
10, 175-180, doi:10.1038/ng0695-175 (1995). 
182 Yang, A. et al. p63 is essential for regenerative proliferation in limb, craniofacial and 
epithelial development. Nature 398, 714-718, doi:10.1038/19539 (1999). 
183 Ramsey, M. R., He, L., Forster, N., Ory, B. & Ellisen, L. W. Physical association of 
HDAC1 and HDAC2 with p63 mediates transcriptional repression and tumor 
maintenance in squamous cell carcinoma. Cancer Res 71, 4373-4379, 
doi:10.1158/0008-5472.CAN-11-0046 (2011). 
184 Re, M. et al. p63 and Ki-67 immunostainings in laryngeal squamous cell carcinoma 
are related to survival. Eur Arch Otorhinolaryngol 271, 1641-1651, 
doi:10.1007/s00405-013-2833-1 (2014). 
185 Gonzalez, R. et al. Role of p63 and p73 isoforms on the cell death in patients with 
hepatocellular carcinoma submitted to orthotopic liver transplantation. PLoS One 12, 
e0174326, doi:10.1371/journal.pone.0174326 (2017). 
186 Stacy, A. J. et al. TIP60 up-regulates DeltaNp63alpha to promote cellular 
proliferation. J Biol Chem 294, 17007-17016, doi:10.1074/jbc.RA119.010388 (2019). 
187 De Laurenzi, V. & Melino, G. Evolution of functions within the p53/p63/p73 family. 
Ann N Y Acad Sci 926, 90-100, doi:10.1111/j.1749-6632.2000.tb05602.x (2000). 
188 Kaghad, M. et al. Monoallelically expressed gene related to p53 at 1p36, a region 
frequently deleted in neuroblastoma and other human cancers. Cell 90, 809-819, 
doi:10.1016/s0092-8674(00)80540-1 (1997). 
189 Ichimiya, S. et al. p73 at chromosome 1p36.3 is lost in advanced stage neuroblastoma 
but its mutation is infrequent. Oncogene 18, 1061-1066, doi:10.1038/sj.onc.1202390 
(1999). 
190 Ishimoto, O. et al. Possible oncogenic potential of DeltaNp73: a newly identified 
isoform of human p73. Cancer Res 62, 636-641 (2002). 
191 Moll, U. M. & Slade, N. p63 and p73: roles in development and tumor formation. Mol 
Cancer Res 2, 371-386 (2004). 




193 Yang, A. et al. p73-deficient mice have neurological, pheromonal and inflammatory 
defects but lack spontaneous tumours. Nature 404, 99-103, doi:10.1038/35003607 
(2000). 
194 Nemajerova, A. & Moll, U. M. Tissue-specific roles of p73 in development and 
homeostasis. J Cell Sci 132, doi:10.1242/jcs.233338 (2019). 
195 Flores, E. R. et al. Tumor predisposition in mice mutant for p63 and p73: evidence for 
broader tumor suppressor functions for the p53 family. Cancer Cell 7, 363-373, 
doi:10.1016/j.ccr.2005.02.019 (2005). 
196 Nemajerova, A. et al. TAp73 is a central transcriptional regulator of airway 
multiciliogenesis. Genes Dev 30, 1300-1312, doi:10.1101/gad.279836.116 (2016). 
197 Lewis, M. & Stracker, T. H. Transcriptional regulation of multiciliated cell 
differentiation. Semin Cell Dev Biol, doi:10.1016/j.semcdb.2020.04.007 (2020). 
198 Tomasini, R., Mak, T. W. & Melino, G. The impact of p53 and p73 on aneuploidy 
and cancer. Trends Cell Biol 18, 244-252, doi:10.1016/j.tcb.2008.03.003 (2008). 
199 Wilhelm, M. T. et al. Isoform-specific p73 knockout mice reveal a novel role for delta 
Np73 in the DNA damage response pathway. Genes Dev 24, 549-560, 
doi:10.1101/gad.1873910 (2010). 
200 Engelmann, D., Meier, C., Alla, V. & Putzer, B. M. A balancing act: orchestrating 
amino-truncated and full-length p73 variants as decisive factors in cancer progression. 
Oncogene 34, 4287-4299, doi:10.1038/onc.2014.365 (2015). 
201 Di, C. et al. Mechanisms, function and clinical applications of DNp73. Cell Cycle 12, 
1861-1867, doi:10.4161/cc.24967 (2013). 
202 Wolf, E. R., McAtarsney, C. P., Bredhold, K. E., Kline, A. M. & Mayo, L. D. Mutant 
and wild-type p53 form complexes with p73 upon phosphorylation by the kinase 
JNK. Sci Signal 11, doi:10.1126/scisignal.aao4170 (2018). 
203 Tannapfel, A. et al. Expression of p73 and its relation to histopathology and prognosis 
in hepatocellular carcinoma. J Natl Cancer Inst 91, 1154-1158, 
doi:10.1093/jnci/91.13.1154 (1999). 
204 Uramoto, H. et al. Expression of deltaNp73 predicts poor prognosis in lung cancer. 
Clin Cancer Res 10, 6905-6911, doi:10.1158/1078-0432.CCR-04-0290 (2004). 
205 Sun, X. F. p73 overexpression is a prognostic factor in patients with colorectal 
adenocarcinoma. Clin Cancer Res 8, 165-170 (2002). 
206 Douc-Rasy, S. et al. DeltaN-p73alpha accumulates in human neuroblastic tumors. Am 
J Pathol 160, 631-639, doi:10.1016/s0002-9440(10)64883-3 (2002). 
207 Dominguez, G. et al. DeltaTAp73 upregulation correlates with poor prognosis in 
human tumors: putative in vivo network involving p73 isoforms, p53, and E2F-1. J 
Clin Oncol 24, 805-815, doi:10.1200/JCO.2005.02.2350 (2006). 
208 Becker, K. et al. Patterns of p73 N-terminal isoform expression and p53 status have 
prognostic value in gynecological cancers. Int J Oncol 29, 889-902 (2006). 
209 Lucena-Araujo, A. R. et al. High DeltaNp73/TAp73 ratio is associated with poor 




210 Ekmekci, C. G., Gutierrez, M. I., Siraj, A. K., Ozbek, U. & Bhatia, K. Aberrant 
methylation of multiple tumor suppressor genes in acute myeloid leukemia. Am J 
Hematol 77, 233-240, doi:10.1002/ajh.20186 (2004). 
211 Irwin, M. S. et al. Chemosensitivity linked to p73 function. Cancer Cell 3, 403-410, 
doi:10.1016/s1535-6108(03)00078-3 (2003). 
212 Gomez, L. C. et al. TP73 DNA methylation and upregulation of DeltaNp73 are 
associated with an adverse prognosis in breast cancer. J Clin Pathol 71, 52-58, 
doi:10.1136/jclinpath-2017-204499 (2018). 
213 Lai, J. et al. TAp73 and DeltaNp73 have opposing roles in 5-aza-2'-deoxycytidine-
induced apoptosis in breast cancer cells. Mol Cells 37, 605-612, 
doi:10.14348/molcells.2014.0154 (2014). 
214 Tophkhane, C. et al. p53 inactivation upregulates p73 expression through E2F-1 
mediated transcription. PLoS One 7, e43564, doi:10.1371/journal.pone.0043564 
(2012). 
215 Vayssade, M. et al. P73 functionally replaces p53 in Adriamycin-treated, p53-
deficient breast cancer cells. Int J Cancer 116, 860-869, doi:10.1002/ijc.21033 
(2005). 
216 Tuve, S., Wagner, S. N., Schittek, B. & Putzer, B. M. Alterations of DeltaTA-p 73 
splice transcripts during melanoma development and progression. Int J Cancer 108, 
162-166, doi:10.1002/ijc.11552 (2004). 
217 Stiewe, T., Zimmermann, S., Frilling, A., Esche, H. & Putzer, B. M. Transactivation-
deficient DeltaTA-p73 acts as an oncogene. Cancer Res 62, 3598-3602 (2002). 
218 Meier, C., Hardtstock, P., Joost, S., Alla, V. & Putzer, B. M. p73 and IGF1R Regulate 
Emergence of Aggressive Cancer Stem-like Features via miR-885-5p Control. 
Cancer Res 76, 197-205, doi:10.1158/0008-5472.CAN-15-1228 (2016). 
219 Stantic, M. et al. TAp73 suppresses tumor angiogenesis through repression of 
proangiogenic cytokines and HIF-1alpha activity. Proc Natl Acad Sci U S A 112, 220-
225, doi:10.1073/pnas.1421697112 (2015). 
220 Shao, J. et al. Overexpression of the wild-type p53 gene inhibits NF-kappaB activity 
and synergizes with aspirin to induce apoptosis in human colon cancer cells. 
Oncogene 19, 726-736, doi:10.1038/sj.onc.1203383 (2000). 
221 Son, D. S., Kabir, S. M., Dong, Y. L., Lee, E. & Adunyah, S. E. Inhibitory effect of 
tumor suppressor p53 on proinflammatory chemokine expression in ovarian cancer 
cells by reducing proteasomal degradation of IkappaB. PLoS One 7, e51116, 
doi:10.1371/journal.pone.0051116 (2012). 
222 Cooks, T. et al. Mutant p53 prolongs NF-kappaB activation and promotes chronic 
inflammation and inflammation-associated colorectal cancer. Cancer Cell 23, 634-
646, doi:10.1016/j.ccr.2013.03.022 (2013). 
223 Vaughan, C. A. et al. p53 mutants induce transcription of NF-kappaB2 in H1299 cells 
through CBP and STAT binding on the NF-kappaB2 promoter and gain of function 
activity. Arch Biochem Biophys 518, 79-88, doi:10.1016/j.abb.2011.12.006 (2012). 
224 Webster, G. A. & Perkins, N. D. Transcriptional cross talk between NF-kappaB and 
p53. Mol Cell Biol 19, 3485-3495, doi:10.1128/mcb.19.5.3485 (1999). 
 
 65 
225 Huang, W. C., Ju, T. K., Hung, M. C. & Chen, C. C. Phosphorylation of CBP by 
IKKalpha promotes cell growth by switching the binding preference of CBP from p53 
to NF-kappaB. Mol Cell 26, 75-87, doi:10.1016/j.molcel.2007.02.019 (2007). 
226 Ravi, R. et al. p53-mediated repression of nuclear factor-kappaB RelA via the 
transcriptional integrator p300. Cancer Res 58, 4531-4536 (1998). 
227 MacPartlin, M. et al. p300 regulates p63 transcriptional activity. J Biol Chem 280, 
30604-30610, doi:10.1074/jbc.M503352200 (2005). 
228 Accardi, R. et al. IkappaB kinase beta promotes cell survival by antagonizing p53 
functions through DeltaNp73alpha phosphorylation and stabilization. Mol Cell Biol 
31, 2210-2226, doi:10.1128/MCB.00964-10 (2011). 
229 Zeng, X. et al. The N-terminal domain of p73 interacts with the CH1 domain of 
p300/CREB binding protein and mediates transcriptional activation and apoptosis. 
Mol Cell Biol 20, 1299-1310, doi:10.1128/mcb.20.4.1299-1310.2000 (2000). 
230 Ryou, S. M. et al. Functional cross-talk between p73beta and NF-kappaB mediated 
by p300. Biochem Biophys Res Commun 345, 623-630, 
doi:10.1016/j.bbrc.2006.04.120 (2006). 
231 Moll, U. M., Erster, S. & Zaika, A. p53, p63 and p73--solos, alliances and feuds 
among family members. Biochim Biophys Acta 1552, 47-59, doi:10.1016/s0304-
419x(01)00036-1 (2001). 
232 Vikhreva, P., Melino, G. & Amelio, I. p73 Alternative Splicing: Exploring a 
Biological Role for the C-Terminal Isoforms. J Mol Biol 430, 1829-1838, 
doi:10.1016/j.jmb.2018.04.034 (2018). 
233 Liu, G. & Chen, X. The C-terminal sterile alpha motif and the extreme C terminus 
regulate the transcriptional activity of the alpha isoform of p73. J Biol Chem 280, 
20111-20119, doi:10.1074/jbc.M413889200 (2005). 
234 Tomasini, R. et al. TAp73 is required for macrophage-mediated innate immunity and 
the resolution of inflammatory responses. Cell Death Differ 20, 293-301, 
doi:10.1038/cdd.2012.123 (2013). 
235 Cooks, T. et al. Mutant p53 cancers reprogram macrophages to tumor supporting 
macrophages via exosomal miR-1246. Nat Commun 9, 771, doi:10.1038/s41467-018-
03224-w (2018). 
236 Ham, S. W. et al. TP53 gain-of-function mutation promotes inflammation in 
glioblastoma. Cell Death Differ 26, 409-425, doi:10.1038/s41418-018-0126-3 (2019). 
237 Walton, J. et al. CRISPR/Cas9-Mediated Trp53 and Brca2 Knockout to Generate 
Improved Murine Models of Ovarian High-Grade Serous Carcinoma. Cancer Res 76, 
6118-6129, doi:10.1158/0008-5472.CAN-16-1272 (2016). 
238 Lin, E. Y. et al. Progression to malignancy in the polyoma middle T oncoprotein 
mouse breast cancer model provides a reliable model for human diseases. Am J 
Pathol 163, 2113-2126, doi:10.1016/S0002-9440(10)63568-7 (2003). 
239 Jamiyan, T., Kuroda, H., Yamaguchi, R., Abe, A. & Hayashi, M. CD68- and CD163-
positive tumor-associated macrophages in triple negative cancer of the breast. 
Virchows Arch, doi:10.1007/s00428-020-02855-z (2020). 
 
66 
240 Hagemann, T. et al. Macrophages induce invasiveness of epithelial cancer cells via 
NF-kappa B and JNK. J Immunol 175, 1197-1205, doi:10.4049/jimmunol.175.2.1197 
(2005). 
241 Naugler, W. E. & Karin, M. NF-kappaB and cancer-identifying targets and 
mechanisms. Curr Opin Genet Dev 18, 19-26, doi:10.1016/j.gde.2008.01.020 (2008). 
242 Lin, J. Y., Li, X. Y., Tadashi, N. & Dong, P. Clinical significance of tumor-associated 
macrophage infiltration in supraglottic laryngeal carcinoma. Chin J Cancer 30, 280-
286, doi:10.5732/cjc.010.10336 (2011). 
243 Chollat-Namy, M. et al. The pharmalogical reactivation of p53 function improves 
breast tumor cell lysis by granzyme B and NK cells through induction of autophagy. 
Cell Death Dis 10, 695, doi:10.1038/s41419-019-1950-1 (2019). 
244 Matsumoto, K. et al. Blockade of NKG2D/NKG2D ligand interaction attenuated 
cardiac remodelling after myocardial infarction. Cardiovasc Res 115, 765-775, 
doi:10.1093/cvr/cvy254 (2019). 
245 Textor, S. et al. Human NK cells are alerted to induction of p53 in cancer cells by 
upregulation of the NKG2D ligands ULBP1 and ULBP2. Cancer Res 71, 5998-6009, 
doi:10.1158/0008-5472.CAN-10-3211 (2011). 
246 Li, H. et al. Pharmacological activation of p53 triggers anticancer innate immune 
response through induction of ULBP2. Cell Cycle 10, 3346-3358, 
doi:10.4161/cc.10.19.17630 (2011). 
247 Soriani, A. et al. Reactive oxygen species- and DNA damage response-dependent NK 
cell activating ligand upregulation occurs at transcriptional levels and requires the 
transcriptional factor E2F1. J Immunol 193, 950-960, doi:10.4049/jimmunol.1400271 
(2014). 
248 Chitadze, G. et al. Shedding of endogenous MHC class I-related chain molecules A 
and B from different human tumor entities: heterogeneous involvement of the "a 
disintegrin and metalloproteases" 10 and 17. Int J Cancer 133, 1557-1566, 
doi:10.1002/ijc.28174 (2013). 
249 Conforti, F., Sayan, A. E., Sreekumar, R. & Sayan, B. S. Regulation of p73 activity 
by post-translational modifications. Cell Death Dis 3, e285, 
doi:10.1038/cddis.2012.27 (2012). 
250 Thor Straten, P. & Garrido, F. Targetless T cells in cancer immunotherapy. J 
Immunother Cancer 4, 23, doi:10.1186/s40425-016-0127-z (2016). 
251 Wang, B., Niu, D. D., Lai, L. Y. & Ren, E. C. p53 increases MHC class I expression 
by upregulating the endoplasmic reticulum aminopeptidase ERAP1. Nat Commun 4, 
doi:ARTN 235910.1038/ncomms3359 (2013). 
252 Birner, P. et al. Overexpression of hypoxia-inducible factor 1alpha is a marker for an 
unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res 60, 4693-
4696 (2000). 
253 Schindl, M. et al. Overexpression of hypoxia-inducible factor 1alpha is associated 
with an unfavorable prognosis in lymph node-positive breast cancer. Clin Cancer Res 
8, 1831-1837 (2002). 
254 Shibaji, T. et al. Prognostic significance of HIF-1 alpha overexpression in human 
pancreatic cancer. Anticancer Res 23, 4721-4727 (2003). 
 
 67 
255 Theodoropoulos, V. E. et al. Hypoxia-inducible factor 1 alpha expression correlates 
with angiogenesis and unfavorable prognosis in bladder cancer. Eur Urol 46, 200-
208, doi:10.1016/j.eururo.2004.04.008 (2004). 
256 Yoshimura, H. et al. Prognostic impact of hypoxia-inducible factors 1alpha and 
2alpha in colorectal cancer patients: correlation with tumor angiogenesis and 
cyclooxygenase-2 expression. Clin Cancer Res 10, 8554-8560, doi:10.1158/1078-
0432.CCR-0946-03 (2004). 
257 Yamamoto, Y. et al. Hypoxia-inducible factor 1alpha is closely linked to an 
aggressive phenotype in breast cancer. Breast Cancer Res Treat 110, 465-475, 
doi:10.1007/s10549-007-9742-1 (2008). 
258 An, W. G. et al. Stabilization of wild-type p53 by hypoxia-inducible factor 1alpha. 
Nature 392, 405-408, doi:10.1038/32925 (1998). 
259 Ravi, R. et al. Regulation of tumor angiogenesis by p53-induced degradation of 
hypoxia-inducible factor 1alpha. Genes Dev 14, 34-44 (2000). 
260 Blagosklonny, M. V. et al. p53 inhibits hypoxia-inducible factor-stimulated 
transcription. J Biol Chem 273, 11995-11998, doi:10.1074/jbc.273.20.11995 (1998). 
261 Schmid, T., Zhou, J., Kohl, R. & Brune, B. p300 relieves p53-evoked transcriptional 
repression of hypoxia-inducible factor-1 (HIF-1). Biochem J 380, 289-295, 
doi:10.1042/BJ20031299 (2004). 
262 Bid, H. K. et al. DeltaNp63 promotes pediatric neuroblastoma and osteosarcoma by 
regulating tumor angiogenesis. Cancer Res 74, 320-329, doi:10.1158/0008-
5472.CAN-13-0894 (2014). 
263 Montagner, M. et al. SHARP1 suppresses breast cancer metastasis by promoting 
degradation of hypoxia-inducible factors. Nature 487, 380-384, 
doi:10.1038/nature11207 (2012). 
264 Amelio, I. et al. TAp73 opposes tumor angiogenesis by promoting hypoxia-inducible 
factor 1alpha degradation. Proc Natl Acad Sci U S A 112, 226-231, 
doi:10.1073/pnas.1410609111 (2015). 
265 Dulloo, I., Hooi, P. B. & Sabapathy, K. Hypoxia-induced DNp73 stabilization 
regulates Vegf-A expression and tumor angiogenesis similar to TAp73. Cell Cycle 14, 
3533-3539, doi:10.1080/15384101.2015.1078038 (2015). 
266 Dulloo, I. et al. Hypoxia-inducible TAp73 supports tumorigenesis by regulating the 
angiogenic transcriptome. Nat Cell Biol 17, 511-523, doi:10.1038/ncb3130 (2015). 
267 Schmid, T., Zhou, J. & Brune, B. HIF-1 and p53: communication of transcription 
factors under hypoxia. J Cell Mol Med 8, 423-431, doi:10.1111/j.1582-
4934.2004.tb00467.x (2004). 
268 Vasiliou, V., Vasiliou, K. & Nebert, D. W. Human ATP-binding cassette (ABC) 
transporter family. Hum Genomics 3, 281-290, doi:10.1186/1479-7364-3-3-281 
(2009). 
269 Rees, D. C., Johnson, E. & Lewinson, O. ABC transporters: the power to change. Nat 
Rev Mol Cell Biol 10, 218-227, doi:10.1038/nrm2646 (2009). 
270 Baldini, N. et al. Expression of P-glycoprotein in high-grade osteosarcomas in 




271 Trock, B. J., Leonessa, F. & Clarke, R. Multidrug resistance in breast cancer: a meta-
analysis of MDR1/gp170 expression and its possible functional significance. J Natl 
Cancer Inst 89, 917-931, doi:10.1093/jnci/89.13.917 (1997). 
272 Luo, Y. et al. Side population cells from human melanoma tumors reveal diverse 
mechanisms for chemoresistance. J Invest Dermatol 132, 2440-2450, 
doi:10.1038/jid.2012.161 (2012). 
273 Chartrain, M. et al. Melanoma chemotherapy leads to the selection of ABCB5-
expressing cells. PLoS One 7, e36762, doi:10.1371/journal.pone.0036762 (2012). 
274 Thottassery, J. V., Zambetti, G. P., Arimori, K., Schuetz, E. G. & Schuetz, J. D. p53-
dependent regulation of MDR1 gene expression causes selective resistance to 
chemotherapeutic agents. Proc Natl Acad Sci U S A 94, 11037-11042, 
doi:10.1073/pnas.94.20.11037 (1997). 
275 Vilgelm, A. et al. DeltaNp73alpha regulates MDR1 expression by inhibiting p53 
function. Oncogene 27, 2170-2176, doi:10.1038/sj.onc.1210862 (2008). 
276 Schatton, T. et al. Identification of cells initiating human melanomas. Nature 451, 
345-349, doi:10.1038/nature06489 (2008). 
277 Petrenko, O., Zaika, A. & Moll, U. M. deltaNp73 facilitates cell immortalization and 
cooperates with oncogenic Ras in cellular transformation in vivo. Mol Cell Biol 23, 
5540-5555, doi:10.1128/mcb.23.16.5540-5555.2003 (2003). 
278 Putzer, B. M. DNp73: oncotarget in invasion and metastasis. Oncotarget 5, 3-4, 
doi:10.18632/oncotarget.1746 (2014). 
279 Castellino, R. C. et al. Overexpressed TP73 induces apoptosis in medulloblastoma. 
BMC Cancer 7, 127, doi:10.1186/1471-2407-7-127 (2007). 
280 Rodhe, J., Kavanagh, E. & Joseph, B. TAp73beta-mediated suppression of cell 
migration requires p57Kip2 control of actin cytoskeleton dynamics. Oncotarget 4, 
289-297, doi:10.18632/oncotarget.833 (2013). 
281 Parmakhtiar, B., Burger, R. A., Kim, J. H. & Fruehauf, J. P. HIF Inactivation of p53 
in Ovarian Cancer Can Be Reversed by Topotecan, Restoring Cisplatin and Paclitaxel 
Sensitivity. Mol Cancer Res 17, 1675-1686, doi:10.1158/1541-7786.MCR-18-1109 
(2019). 
282 Chen, J. et al. HIF-1alpha inhibition reverses multidrug resistance in colon cancer 
cells via downregulation of MDR1/P-glycoprotein. PLoS One 9, e98882, 
doi:10.1371/journal.pone.0098882 (2014). 
283 Bentires-Alj, M. et al. NF-kappaB transcription factor induces drug resistance 
through MDR1 expression in cancer cells. Oncogene 22, 90-97, 
doi:10.1038/sj.onc.1206056 (2003). 
284 Dyson, H. J. & Wright, P. E. Role of Intrinsic Protein Disorder in the Function and 
Interactions of the Transcriptional Coactivators CREB-binding Protein (CBP) and 
p300. J Biol Chem 291, 6714-6722, doi:10.1074/jbc.R115.692020 (2016). 
 
